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Prologue 
This document contains two separate six-month research projects completed for the degree of 
MRes in Molecular and Cellular Biology. The first project was concerned with the 
development of targeted therapies for progressive, treatment-resistant forms of B-cell chronic 
lymphocytic leukaemia (B-CLL) that exhibit functional loss of the Ataxia-telangiectasia 
mutated (ATM) gene. B-CLL is currently incurable, and available palliative treatments are 
relatively toxic to patients, the majority of which fall within an aging demographic. ATM loss 
is linked to highly aggressive forms, and results in defective homologous recombination and 
therefore a diminished capacity for the efficient repair of DNA double-strand breaks. While 
this promotes genomic instability and ultimately cancer, it also leaves the cell vulnerable to 
the accumulation of catastrophic DNA damage levels if other routes of DNA repair are 
inhibited. The aim of the project was to therefore investigate the effectiveness of novel, less 
toxic therapeutic compounds that exploit this mechanism of synthetic lethality - specifically, 
poly (ADP-ribose) polymerase and histone deacetylase inhibitors.  
The second project report details an optimisation study contributing to the development of a 
histopathological tissue imaging method. The method utilises indirect immunofluorescence 
and confocal laser-scanning microscopy (CLSM) to enable the simultaneous visualisation of 
multiple biomarkers within tissue cryosections. The development of such a method is 
beneficial to histology and histopathology, as it provides a reliable method of multiple antigen 
visualisation, allowing for the analysis of spatial and temporal relationships between 
molecules, the cell types that express them and the tissue components comprised of such cells. 
Specifically, staining and imaging protocols were optimised for use on reactive lymph node 
cryosections, for the simultaneous visualisation of the B-lymphocyte surface markers CD19, 
κ- and λ- immunoglobulin light chain antigens. Older generation fluorophores were replaced 
  
with newer, more photostable and generally brighter Alexa fluorophores, increasing the 
viability and applicability of the method for both diagnostic and experimental histopathology. 
The main theme running across the two projects is that of research into haematological 
malignancies, particularly B-CLL. Whilst the first is directly involved in the development of 
targeted cancer therapy, the tissue imaging method optimised in the second can be further 
developed for spatial immunophenotyping of specific cancer biomarkers within diseased 
immunological tissues. This is of use to biomedical research for the development of targeted 
cancer therapies based on the specific molecular mechanisms of disease, as well as from a 
clinical perspective for establishing disease diagnoses and prognoses based on the molecular 
profile of individual leukaemias and lymphatic lymphomas. The conclusions drawn from both 
projects will hopefully contribute towards research into haematological malignancies and 
benefit cancer research as a whole. 
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Abstract 
Progressive B-Cell Chronic Lymphocytic Leukaemia (B-CLL) represents a clinical problem 
due to its aggressive disease course and poor survival rate. Many progressive B-CLL forms 
are characterised by a loss of the ataxia telangiectasia mutated (ATM) and/or TP53 tumour 
suppressor and DNA damage repair genes, the incidence of which is associated with 
resistance to therapies that rely on DNA-damage induced apoptosis. The loss of these genes, 
particularly ATM, results in defective homologous recombination (HR). Previous studies 
have found that Poly (ADP-ribose) polymerase inhibitors (PARPis) impose the requirement 
of HR and selectively sensitise ATM deficient cells to killing. This study assessed the 
potential of combining histone deacetylase inhibitors (HDACis) to synergise with PARP 
inhibitors and increase this selective killing effect. Conversely, CII and TP53 mutant MEC-1 
isogenic B-CLL cell lines that were treated with ATM shRNA did not exhibit significant 
sensitivity to PARP inhibition, nor show convincing evidence of selective PARPi/HDACi 
synergy. TP53 mutant cells showed no sensitivity to PARP inhibition regardless of ATM 
status. TP53 mutant cells exhibited increased proliferation at low HDACi doses, although 
lower doses of HDAC inhibitor was more cytotoxic to p53 mutant MEC-1 cells overall, and 
also to ATM wild type cells in both cell lines. However, complete ATM knockdown was not 
achieved in CII cells and HR was not found to be seriously compromised. Thus, further 
detailed studies and alternative assay methods are required before any conclusions can be 
drawn on the synergic potential of PARP and HDAC inhibitors in the treatment of HR-
deficient progressive B-CLL. 
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1.0 Introduction 
1.1 B-Cell Chronic Lymphocytic Leukaemia 
 B-Cell Chronic Lymphocytic Leukaemia (B-CLL) is the most common haematological 
malignancy in the Western world, with the majority of patients over 60 years of age and males 
outnumbering females 2:1 (Damle et al., 1999).  The pathology itself is caused by the 
relentless accumulation of redundant monoclonal B cells that morphologically resemble small 
mature lymphocytes (Hamblin et al., 1999). B-CLL tumour cells have characteristic 
immunophenotypes, typically being positive for CD5, CD19 and CD23 markers but negative 
for surface CD22 and FMC7 (Hamblin et al., 1999). B-CLL tumour cells express 10-fold 
lower amounts of surface Ig than mature B cells, the isotypes normally being IgM or a 
combination of IgM and IgD. Very reduced levels of IgM are also secreted, highlighting their 
functional redundancy (Friedman et al., 1992). B-CLL disease progression is the most 
heterogeneous of all leukaemias (Cramer and Hallek, 2011). B-CLL remains at present 
incurable, and current treatments induce transitory remission rather than achieve total 
eradication of the disease (Chiorazzi et al., 2005; Damle et al., 1999). Some disease forms are 
relatively stable and require little or no treatment, while others are highly aggressive and have 
a poor clinical outcome, known as progressive CLL (Austen et al., 2007; Weston et al., 2010).  
As a result of this clinical heterogeneity, there has been an emphasis on identifying unique 
characteristics that allow foresight of the clinical course of individual B-CLL patients. A 
“naive” tumour cell phenotype, characterised by unmutated IgVH genes, is a poor prognostic 
indicator (Damle et al., 1999; Hamblin et al., 1999), as is expression of the CD38 surface 
marker (Damle et al., 1999; Pittner et al., 2005). ZAP-70 is a tyrosine kinase that is 
exclusively expressed in T and natural killer (NK) cells, but aberrantly expressed by B cells in 
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some forms of B-CLL, greatly reducing life expectancy and clinical outcome (Hamblin et al., 
1999; Ure et al., 2009). Expression of the anti-apoptotic gene Mcl-1 may also indicate 
progressive B-CLL (Pepper et al., 2008). Cytogenetic abnormalities are also often present, 
and are also important indicators of severity. 11q and 17p deletions are indicators of very poor 
clinical prognosis and highly aggressive disease courses, as these are the sites of the DNA 
damage response and cell cycle regulator genes Ataxia telangiectasia mutated (ATM, fig. 1) 
and p53 respectively (Austen et al., 2005; Dohner et al., 1995; Stankovic et al., 2002b).  
1.2 ATM and p53 
Defective ATM expression results in progressive B-CLL because of the function and nature 
of the gene (fig. 1). ATM belongs to the phosphatidylinositol 3-kinase-related kinase (PIKK) 
superfamily, which also includes ataxia telangiectasia and RAD3-related (ATR), DNA-
dependent protein kinase catalytic subunit (DNA-PKcs) and mammalian target of rapomycin 
(mTOR) (Zhou et al., 2006). The gene is located on chromosome 11q23-24, and its numerous 
roles involve cell cycle regulation, control of telomere length and DNA processing, though its 
main function is that of a DNA damage sensor and DNA damage response (DDR) integrator, 
particularly concerning DNA double-strand breaks (DSBs). The protein product is 350kDa in 
size, and possesses a C-terminal PI3-kinase domain. ATM phosphorylates downstream 
proteins to relay DNA damage signals, and recruits DNA repair proteins to sites of DNA 
damage (Austen et al., 2005; Lavin and Khanna, 1999; Savitsky et al., 1995; Stankovic et al., 
2002a; Starczynski et al., 2003; Weston et al., 2010). Biallelic loss of the ATM gene is solely 
Figure 1 – Functional diagram of ATM, a 350kDa protein containing 3056 amino acids. Pictured are the five main 
functional domains and autophosphorylation sites. The HEAT repeats bind directly to the C terminal of NBS1, a member of 
the MRN DSB repair complex. The FAT domain interacts with the catalytic-site containing PI3K domain and stabilises the 
C-terminal region of the ATM protein, while the PRD and FATC domains regulate the kinase activity of the PI3K region. 
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responsible for the rare autosomal recessive inherited condition ataxia telangiectasia (A-T), 
the defining symptoms of which include an unsteady gait (ataxia) and visibly dilated blood 
vessels in the eye conjunctiva and facial region (telangiectases) (Savitsky et al., 1995; Taylor 
et al., 1975).  
In accordance with the role of ATM in mediating the DSB response, A-T sufferers exhibit an 
increased sensitivity to ionising radiation (IR) and predisposition to lymphoreticular 
malignancies (Taylor et al., 1975). ATM-deficient cells also exhibit inherent chromosomal 
instability and delayed p53 activation/cell cycle arrest in response to DNA damage (Savitsky 
et al., 1995). This therefore explains how sporadic ATM mutations/11q deletions may 
promote progressive B-CLL through unrepaired DNA and subsequent chromosomal 
instability (Stankovic et al., 2002b). ATM is involved with the same DNA damage response 
pathway as p53, though the roles are not completely congruent – ATM deficiency results in 
increased sensitivity to IR, whilst p53 loss confers radioresistance (Alvi et al., 2005; Savitsky 
et al., 1995; Stankovic et al., 2002b).  
1.3 Mechanisms of ATM loss 
As well as 11q deleted forms of ATM-null B-CLL, ATM is the single most frequently 
mutated gene in B-CLL (Stankovic et al., 2002b).  The reasons for why ATM dysfunction is 
such a common occurrence in progressive B-CLL are widely unknown.  ATM is 
downregulated during lymphocyte germinal development and V(D)J recombination, a period 
during which physiological DNA DSBs must occur (Starczynski et al., 2003), although ATM 
dysfunction is linked with, but not exclusive to, unmutated IgVH gene disease forms 
(Stankovic et al., 2002b). Also, unlike A-T which is caused by the inheritance of homozygous 
ATM defective alleles, it is not thought that an inherited dysfunctional ATM allele bestows a 
predisposition to B-CLL disease onset. It is, however, likely that sporadic loss-of-function 
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mutations will occur in the one remaining allele if B-CLL arises, and thus the possession of a 
defective ATM allele predisposes B-CLL patients to progressive forms of the disease 
(Skowronska et al., 2012). Whatever the genetic basis of ATM dysfunction, the clinical effect 
is certain - ATM mutations and/ or 11q deletions lead to rapid clonal expansion of ATM null 
tumour cells (Austen et al., 2007), thereby reducing progression-free survival rates as well as 
overall patient survival (Austen et al., 2007; Weston et al., 2010).  
1.4 Current treatments for ATM-deficient progressive B-CLL 
  Commonly used progressive B-CLL treatments involve combinations of DNA-damage 
inducing nucleoside analogues and alkylating agents, leading to the subsequent induction of 
apoptosis via p53/ATM pathways (Austen et al., 2005; Austen et al., 2007; Maddocks and 
Lin, 2009; Pettitt, 2003). However, ATM mutant or 11qdel B-CLL forms are deficient in 
these pathways and thus exhibit resistance to these approaches (Weston et al., 2010). Indeed, 
p53 mutant B-CLL tumours exhibit little or no apoptotic response in vitro, whilst ATM 
mutant tumours exhibit a markedly reduced response (Stankovic et al., 2002b; Stankovic et 
al., 2004). Recently, the addition of the CD20-targeting chimeric monoclonal antibody 
rituximab to fludarabine and cyclophosphamide front-line regimens paired with second line 
alemtuzumab and flavopiridol has had some clinical success (Weston et al., 2010). A positive 
response to the CDK inhibitor R-roscovitine (CYC202) has also been observed, which 
appeared to resensitise p53/ATM pathway-deficient B-CLL tumours to DNA-
damage/apoptosis inducing treatments (Alvi et al., 2005). However, these approaches still rely 
on traditional DNA damaging treatments and chemotherapeutics which broadly target rapidly 
dividing cells, resulting in clinical complications such as toxicity and immunosuppression 
(Weston et al., 2010). Thus, treatments are required that are not only more effective against 
ATM defective tumours, but also more specific to neoplastic cells and less toxic to patients, 
especially because most progressive B-CLL sufferers are above 60 and therefore less tolerant 
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of adverse side effects. Because of the function of the ATM gene, a promising novel approach 
in treating ATM-deficient B-CLL is to exploit the concept of synthetic lethality in DNA 
repair pathways. To understand why this may be the case, some common mechanisms of 
DNA repair are introduced. 
1.5 The DNA damage response, cancer and 
synthetic lethality as a novel therapeutic 
strategy 
The DNA damage response (DDR) is a complex 
cellular process. There are five main DNA 
damage response mechanisms known, which can 
be divided into single strand break (SSB) repair 
and double strand break (DSB) repair. DSBs are 
most serious and lead to genomic and 
chromosomal instability, and can lead to 
apoptosis if left unrepaired (Shaheen et al., 
2011). DSBs can be repaired via the more 
accurate homologous recombination (HR) 
mechanism, which utilises homologous 
chromatid sequences as templates to synthesise 
DNA across a DSB. HR occurs in the 
synthesis/gap 2/mitosis (S/G2/M) cell cycle 
stages. The other main DSB repair mechanism is 
Figure 2 - DSB repair mechanisms, HR, and NHEJ, 
and their two sub-pathways. Some molecular 
mediators of each process are also pictured (Shaheen 
et al., 2011). 
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non-homologous end joining (NHEJ), which involves the direct ligation of free ends of the 
DSB, and is much more prone to error (Shaheen et al., 2011). NHEJ occurs in the G0-G1 
phases of the cell cycle. Both of these methods have two sub-pathways (fig. 2).  
The DDR is a potentially targetable mechanism for novel cancer therapeutics. The term 
“synthetic lethality” is defined by two genes in a relationship whereby the dysfunction of one 
gene is not detrimental to cell survival, but the loss of both genes simultaneously results in 
cell death (Helleday et al., 2008; Shaheen et al., 2011). This concept is the basis that such 
novel therapeutics that target the DDR are based around. Cancer itself is a disease of aberrant 
DNA repair mechanisms, as unrepaired DNA leads to genomic instability and subsequent 
malignancies (Shaheen et al., 2011). However, cancer cells still require other DNA repair 
mechanisms to remain functional in order for them to survive. For this reason, cancer cells 
that are defective in particular DNA repair mechanisms may become dependent on other still-
functioning sub-pathways. By disrupting these remaining pathways via the inhibition of 
essential mediators, the cancer cell is unable to repair its genome and is destroyed through 
catastrophic accumulation of irreparable DNA damage (Audeh et al., 2010; Chiarugi, 2012; 
Shaheen et al., 2011; Weston et al., 2010; Yap et al., 2011). Other healthy cells without the 
DDR mutations would repair the damage and remain unaffected, and therefore this approach 
should be less toxic than standard DNA damage inducing agents (Weston et al., 2010). 
The heavy involvement of ATM in the DNA damage response means that cancers deficient in 
ATM are good targets for these synthetic lethal approaches. ATM is the principal integrator of 
the DDR for DSBs, and directly phosphorylates HR mediators such as BRCA, Nbs-1 and 
Rad51 upon detection of DNA damage (Cortez et al., 1999; Starczynski et al., 2003). ATM is 
also a mediator of NHEJ responses and has been shown to function alongside the NHEJ 
mediators Artemis and DNA-PKcs (fig. 2), although ATM is not a core component unlike in 
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HR (Riballo et al., 2004). Collectively, ATM-mutant B-CLL tumours may be vulnerable to 
therapies targeting redundant DNA repair pathways independent of ATM (Weston et al., 
2010). One such mediator of these sub-pathways are the poly (ADP-ribose) polymerases 
(PARPs). 
1.6 Synthetic lethality in practice: PARP inhibition 
 The PARP family consists of 18 enzymes. PARPs catalyse the poly(ADP-ribosyl)ation of 
proteins, a process whereby ADP-ribose polymers are formed from donor NAD+ molecules 
and attached to proteins via ester bonding with glutamic acids, aspartic acids or lysine 
residues (Woodhouse and Dianov, 2008). Poly(ADP – ribosyl)ation is a ubiquitous cellular 
process, and two members of the PARP family, PARP1 and PARP2, are known to play active 
roles in DNA repair. PARP1 shows significant overlap and is active in both DSB and SSB 
repair. For DSBs, PARP1 aids exposure 
of ssDNA by promoting DNA end 
resection via EXO1 and BLM, thus 
assisting HR (fig. 2). PARP1 also 
promotes the less accurate alternative 
NHEJ pathway (Wang et al., 2006) (fig. 
2). For SSB repair, PARP1 is a mediator 
of the base excision repair (BER) 
mechanism (Shaheen et al., 2011). 
These roles in the DDR therefore make 
PARP1 an attractive target for synthetic 
lethal cancer therapy approaches, as 
Figure 3 - Proposed mechanism of synthetic lethality when 
PARP1 is inhibited in an ATM deficient tumour undergoing 
deregulated replication. 
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they mediate DDR mechanisms that HR deficient cancers may rely on. 
PARP inhibitors (PARPis) have already proven to be an effective strategy in cancers such as 
BRCA-deficient breast and ovarian cancer and ATM deficient B-CLL (Audeh et al., 2010; 
Fong et al., 2010; Weston et al., 2010). BRCA1 and BRCA2 are major mediators of HR, and 
BRCA requires phosphorylation via ATM to function, hence in these cancers HR is 
compromised (Cortez et al., 1999). Thus, ATM and BRCA deficient cells are dependent on 
PARP1-mediated DNA DSB repair processes such as alternative NHEJ and single-strand 
annealing (SSA,  fig.2), and PARP1 inhibition also removes these options. BER is also 
compromised without PARP1 function, meaning that SSBs go unrepaired and are converted 
to DSBs during DNA replication. ATM deficient cells cannot repair these DSBs via HR, the 
result of which is the accumulation of DSBs and mitotic catastrophe (Weston et al., 2010) 
(fig. 3). Importantly, the highly proliferative nature of ATM deficient tumours contributes to 
the killing mechanism because the increased frequency of DNA replication leads to more and 
more unrepaired DSBs (Weston et al., 2010). 
From a clinical perspective, olaparib (AZD2281) is one of the most commonly used PARP 
inhibitors, and is credited with being fairly well tolerated and having high oral bioavailability 
(Audeh et al., 2010). Side effects are generally manageable and include fatigue, nausea and 
lymphocytopenia (Vasiliou et al., 2009). Olaparib can be used as a single agent or in 
conjunction with cytotoxic drugs, DNA damage inducers such as platinum-based compounds, 
or radiotherapy (Vasiliou et al., 2009). Initial clinical trials of olaparib on BRCA1 and 2 
compromised breast and ovarian cancers have yielded positive results (Audeh et al., 2010; 
Fong et al., 2010).  Previous in vitro studies have also highlighted the effectiveness of 
Olaparib in the specific killing of ATM-deficient B-CLL tumour cells (Weston et al., 2010). 
Olaparib is currently undergoing clinical trials in B-CLL for patients that are not responding 
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to conventional treatment. It is also undergoing clinical trials for the treatment of T-
prolymphocytic leukaemia (T-PLL) and mantle cell lymphoma (MCL), haematological 
malignancies in which ATM dysfunction is also common (Weston et al., 2010). ATM-
deficient B-CLL patients are currently participating in phase II trials with olaparib (Pratt, 
2011).  
1.7 PARPi resistance 
 Although PARPi therapy has been generally well received, there have recently been 
numerous reports of resistance to PARPis, posing a potential clinical problem to PARPi 
monotherapy. For example, in BRCA
-/-
 and p53
-/-
 mammary adenocarcinomas transplanted 
into mice, olaparib was initially shown to have potent anti-tumour effects, but resulted in 
eventual tumour growth relapse during treatment as well as after discontinuation (Rottenberg 
et al., 2008). Interestingly, a contributor to this resistance was found to be due to the PARPi-
induced upregulation of Abcb1a/b P-glycoprotein efflux pump genes, which remove 
xenobiotics from cells and are often a problem in chemotherapeutic resistance (Wurzer et al., 
2000). It has also been reported that  PARP1 itself may ribosylate and inhibit members of the 
ABC transporter family such as P-glycoprotein pumps, and thus the inhibition of PARP1 may 
actually contribute to the extrusion of the inhibitor compound (Dumitriu et al., 2004). In 
addition, there have been reports of HR mechanisms being restored in PARPi-treated BRCA1 
or -2 deficient cells, suggesting that the increased genomic instability stemming from 
inhibition of PARP1 could induce restorative mutations in BRCA genes (Edwards et al., 
2008).  These observations suggest that PARPi monotherapy may not be an effective long 
term strategy.  
These phenomena have not yet been observed in ATM-deficient B-CLL, however, and the 
induction of synthetic lethality via PARPi is still a promising option. The concept of using 
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PARPis as sensitising agents to radiotherapy and traditional DNA damage inducing 
chemotherapeutic methods, such as platinum salts, is a strategy that some groups have 
explored (Rottenberg et al., 2008). The toxicity of these compounds is still a problem, 
however, especially because the majority of progressive B-CLL sufferers are elderly. The 
optimum chemotherapeutic compounds to use in combination with PARPi are also yet to be 
resolved (Yap et al., 2011). One method of increasing the tumour-killing effectiveness of 
PARPis and possibly counteracting these observations of PARPi resistance could be to 
administer PARPis alongside other novel and less toxic DNA-damage response targeting 
compounds, to further increase the synthetic lethal effects of DDR inhibition on HR deficient 
tumours. One potential molecular target is the histone deacetylase (HDAC) family, which, 
amongst numerous other roles, are implicated heavily in the DDR. 
1.8 HDAC functions 
  HDACs are antagonistic to histone acetyltransferases (HATs), which transfer the acetyl 
group from acetyl CoA to lysine residues on proteins, forming ε-N-acetyl lysines (fig. 4). This 
process, termed acetylation, is essential for many cell processes. The most prominent of these 
processes is the regulation of chromatin dynamics. HATs acetylate conserved lysines on the 
N-terminal tails of histones H3 and H4, as well as H2A and H2B to a lesser extent (Federico 
and Bagella, 2011). This confers an open nucleosomal structure, termed euchromatin, which 
is more accessible to transcriptional machinery and thus more conducible to gene 
transcription. HDACs oppose this action, and deacetylate histones to revert chromatin back to 
a more condensed form, heterochromatin (fig. 4). Thus, HDACs are negative regulators of 
gene expression (Federico and Bagella, 2011).  
18 mammalian HDACs are known, which fall into 4 groups. Class I HDACs are all nuclear 
and ubiquitously expressed. Class II HDACs are thought to shuttle between the nucleus and 
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cytoplasm and are tissue specific. Class III HDACs include the NAD
+
-dependent sirtuin 
HDACs, while class IV contains only one HDAC, HDAC11 (Federico and Bagella, 2011). 
Some HDACs, such as the Class I HDACs HDAC 1 and HDAC2, have been found to be 
overexpressed in many cancers. Similarly, HDAC ablation often results in a loss of 
proliferation and/or apoptosis induction highlighting their tumorigenic properties (Jurkin et 
al., 2011). 
As HDACs are mainly negative gene regulators due to the effects on chromatin, HDAC 
inhibition results in widespread gene upregulation (fig. 4), which can have anti-cancer effects. 
Aberrantly silenced tumour suppressor genes may be upregulated, such as p21
WAF1
, p27
KIP
 
and p16
ink4a 
(Marks et al., 2000; Richon et al., 2000). HDAC inhibitors may also cause the 
upregulation of pro-apoptotic factors, such as Bim and TRAIL (Nebbioso et al., 2005; Tan et 
al., 2005) or result in repression of survival factors such as survivin (Chowdhury et al., 2011). 
However, acetylation is not only restricted to histones and chromatin dynamics. Thus, 
HDACs have a wide range of other targets, including oncogenic transcription factors and 
tumour suppressors that are involved with progression of certain cancers. Some examples 
include p53 (Gu and Roeder, 1997), E2F (Martinez-Balbas et al., 2000), c-Myc (Patel et al., 
2004) and NF-κB (Chen et al., 2001). It is therefore no surprise that HDAC activity is often 
altered in cancer. HDACs have also been directly linked with the function of oncogenic 
translocation products in lymphomas and leukaemias, such as PML-RARα in acute 
promyelocytic leukaemia (APL) (Matsushita et al., 2006).  
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Collectively, it is clear that HDACs are important in cancer progression for many reasons. 
However, the role of HDACs in the DDR is of particular interest to this study, because 
HDACs are therefore potential targets for synthetic lethal strategies in the treatment of B-CLL 
(Robert et al., 2011). 
1.9 HDACs in DNA repair 
 In the event of DNA damage, histones undergo many post-translational modifications 
(PTMs) that impact on the DNA repair process itself or the chromatin restoration step, 
acetylation being one of the most important forms (Corpet and Almouzni, 2009). Lysines 
H3K9 (Tjeertes et al., 2009) and H3K56 (Miller et al., 2010; Yuan et al., 2009) are 
deacetylated in the event of DNA damage, and result in genomic instability in yeast and 
mammals if not deacetylated by HDACs in the event of DNA DSBs (Yuan et al., 2009). The 
precise mechanisms by which the acetylation status of these histones affects DNA damage 
responses are largely unknown, but H3K56 is close to the DNA entry/exit point of the 
nucleosome core and this acetylation may affect nucleosomal stability (Groth et al., 2007). 
HDACs, chromatin dynamics and ATM have also been directly linked in the DDR. For 
Figure 4 - A basic representation of the effects of HDAC inhibition on chromatin dynamics and a summary of some 
resulting cellular responses. 
 16 
 
example, the ATM-Chk2 pathway may be required for completion of DNA repair, H3K56 re-
acetylation and cell-cycle resumption after ultraviolet (UV)-induced DNA damage (Battu et 
al., 2011). UV damage usually results in SSBs repaired by nucleotide excision repair (NER), 
mediated by the ATR-Chk1 pathway, highlighting the high levels of crosstalk of DDR 
mediators (Battu et al., 2011). There is also evidence to suggest that in the event of HDAC 
inhibition, ATM can act as a transcription modulator and upregulate expression of anti-
apoptotic genes such as MCL-1 (Jang et al., 2010), thus HDACis may be more effective on 
ATM deficient tumours. 
HDACs are also involved in HR. The idea of HDAC involvement in HR is counterintuitive, 
because euchromatic DSBs are far more conducible to HR than heterochromatic DSBs 
(Chiolo et al., 2011). Thus, HDACs are more likely to play direct roles in HR rather than 
regulating chromatin dynamics. Indeed, this has been observed in yeast, whereby the 
recombination protein Sae2 is acetylated and degraded when HDACs are inhibited (Robert et 
al., 2011). HDAC1 and -2 are mediators of DSB repair, particularly acting on NHEJ effector 
proteins (Miller et al., 2010).  
HDACis have also been found to actively induce cell killing through autophagy, due to the 
induction of reactive oxygen species (ROS) and subsequent DNA damage (Fu et al., 2010; 
Robert et al., 2011). This tumour-suppressive action is independent of apoptosis, and has been 
shown to be effective in several resistant forms of cancer. This is therefore an attractive 
mechanism to explore in treatment-resistant B-CLL forms.  
Collectively, the roles of HDACs in the DDR are clearly very complex and convoluted. 
However, regardless of the underlying mechanism, it is clear that HDACs are important in the 
DNA damage response, and HDAC inhibitors are therefore a viable therapeutic strategy in the 
treatment of ATM-deficient B-CLL.  
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1.10 HDAC inhibitor classes 
 HDAC inhibitors can be divided into four distinct structural classes. These are the small 
molecular weight carboxylates; hydroxamic acids; benzamides and cyclic peptides. Some 
inhibitors target only specific HDACs or classes of HDACs, while others target a wider range, 
termed pan-HDAC inhibitors. All currently known HDAC inhibitors target the zinc molecule 
present within the active site of Class I, II and IV HDACs (Federico and Bagella, 2011). It has 
been observed that H3K9 and H3K56 remain broadly acetylated in the event of DNA damage 
when each of these classes are inhibited, whilst only mild acetylation remains with class III 
sirtuin HDACis (Tjeertes et al., 2009). This suggests that class III HDACs may not contribute 
as much as other classes to HDAC DNA damage responses. Conversely, another study 
reported that H3K56 acetylation increased when SIRT1, a class III HDAC, was inhibited, thus 
the mechanism remains unclear (Yuan et al., 2009). Many HDACis have been approved for 
clinical trials, and most have yielded positive results with relatively mild toxicity (Ellis and 
Pili, 2010; Federico and Bagella, 2011). There have been reports of HDACi related 
cardiotoxicity, but the most common effects include fatigue, transient thrombocytopenia and 
relatively mild gastrointestinal complications such as nausea, vomiting and diarrhoea 
(Federico and Bagella, 2011). Monotherapeutic approaches with HDACis have shown fair 
anti-tumour activity, but like PARP inhibitors, the true potential for HDACis probably lies in 
combination with other therapies (Ellis and Pili, 2010). 
1.11 Aims 
 Like PARP inhibition, the involvement of HDACs in the DNA damage response opens 
possibilities of using HDAC inhibitors as radiosensitisers or chemosensitisers (Camphausen 
and Tofilon, 2007; Miller et al., 2010; Robert et al., 2011). It has already been shown that 
PARP and HDAC inhibitors synergise to upregulate DNA damage-induced apoptosis in the 
HCT116 colon cancer cell line (Adimoolam et al., 2007).  However, in the absence of 
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ATM/p53 mediated apoptosis in DNA damage, PARP inhibitors induce cytotoxicity through 
unrepaired DNA damage, and it is highly possible that HDACis can increase this effect 
(Weston et al., 2010).  
As previously discussed, PARP1 and HDACs mediate various DDR responses, and there is 
much ambiguity and crosstalk between the individual DDR mechanisms and their 
corresponding molecular pathways. In the absence of ATM and thus efficient HR, ATM-null 
B-CLL tumours may place a higher dependency on PARP/HDACs for coordinating DNA 
repair responses. As also discussed, the novel therapeutic potential of PARP and HDAC 
inhibition alone in HR-compromised cancers has been extensively reported. As the DNA 
damage response is such a complex and convoluted network, using both PARP and HDAC 
inhibitors in combination may result in synergy and heighten the synthetic lethal effect on 
ATM-deficient B-CLL tumours, because further DDR mediators that HR deficient cells may 
fall back on are inhibited. The recently reported abilities of HDACis to induce DNA damage 
and autophagic tumour killing independent of apoptosis are also promising. Based on these 
speculations, it was therefore hypothesised that treatment with PARP inhibitors would render 
ATM-deficient B-CLL tumours preferentially sensitive to further treatment with HDAC 
inhibitors, producing a synergistic tumour-killing effect more potent than PARP inhibition or 
HDAC inhibition alone. Indeed, some evidence for this has already been observed, but not 
confirmed (Weston et al., 2010).  
The primary aim of this project was to further investigate the therapeutic potential for the use 
of HDAC inhibitors alongside PARP inhibitors in the treatment of ATM-deficient progressive 
B-CLL. A side aim was to also assess the effects of the drugs on p53 mutant cells of differing 
ATM status. The study objectives were to: 
  identify ATM mutants in a cohort of 28 B-CLL patients  
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  assess the tumour killing effectiveness of PARP and HDAC inhibitors in vitro 
 investigate the synergic potential of PARPi/HDACi combined therapy in ATM  
and/or p53 deficient B-CLL tumour cell killing and the mechanisms by which this 
synergy is driven. 
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2.0 Materials and Methods 
2.1 B-CLL patient tumour sample preparation 
 Human peripheral blood samples were obtained from B-CLL patients from Birmingham and 
Bournemouth hospitals. To extract tumour cells, the samples were made up to a volume of 30 
ml with RPMI 1640 cell culture media with glutamine (Invitrogen) and pipetted onto 20 ml 
lymphoprep (Axis-Shield) in falcon tubes. The samples were then centrifuged at 1,600 RPM 
for 30 minutes with deceleration brake disabled (Beckman Coulter Allegra X-12 Centrifuge). 
The B-CLL tumour cells were extracted and washed in RPMI 1640 media, and stored at -
160
o
C in 90% foetal calf serum (FCS, Sigma) with 10% dimethyl sulfoxide (DMSO, Sigma) 
at a density of 5x10
7
 cells/ml.   
2.2 Genomic DNA extraction 
 B-CLL tumour cell samples as prepared above were thawed at RT and washed in 20 ml 
RPMI 1640 media (Invitrogen) and washed twice in 20 ml dulbecco’s phosphate-buffered 
saline (DPBS). DNA was extracted to manufacturers protocol using a Flexigene DNA kit 250 
(QIAgen), resulting in genomic DNA samples resuspended in 200 μl FG3 Buffer (QIAgen).  
2.3 DNA purification 
 Sodium acetate (20 μl at 3 M) and 400 μl pure ethanol (PAA) was added to the DNA samples 
and the DNA left to precipitate for 1 hour at -80 
o
C. The solution was span at 13,000 RPM for 
30 minutes at 4 
o
C, the DNA pellet washed in 500 μl 70% ethanol and resuspended in FG3 
buffer (QIAgen). DNA concentration and purity was measured via spectrophotometry (Implen 
Nanophotometer) and diluted to final concentrations of 10 ng/μl in FG3 buffer (QIAgen).  
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2.4 LightScanner mutation analysis (Hi-Res Melting) 
Hi-Res melting, using 
LightScanner and Call-IT 
software (Idaho 
Technologies), is a novel 
high-throughput technique 
whereby many samples can be 
analysed for potential DNA 
sequence changes 
simultaneously. The process 
involves polymerase chain 
reaction (PCR) being 
simultaneously carried out on 
both forward and reverse 
strands of an exon of interest, 
in the presence of a 
fluorescent dye, LCgreen 
(Idaho Technologies), that intercalates between bases in double-helix DNA molecules. The 
dye is inactive when free, but fluoresces when intercalated with DNA in a closed double helix 
conformation, which occurs as a result of spontaneous annealing of forward and reverse 
strands. Fluorescence levels can be quantified to give a measure of PCR product amount. By 
incrementally increasing the temperature of the DNA molecule to the point at which double 
strand DNA (dsDNA) will dissociate into single strand DNA (ssDNA), also resulting in 
dissociation of the dye, a DNA melting curve profile can be obtained by comparing relative 
fluorescence levels against temperature. The simultaneous heating of exons of multiple 
Figure 5 – Hi-Res Melting analysis. A. Melting Curves of individual samples for 
ATM exon 10. B. Normalised fluorescence levels. C. Isolating potential sequence 
variants via level of deviance relative to the standard curve. Green curves 
represent potential sequence variants while red curves represent a potential group 
of similar sequence variants. 
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patients allows for the direct comparison of individual DNA melting profiles against each 
other and a known wild-type (WT) profile (fig. 5). Differential melting curve characteristics 
denotes a change in the kinetic properties of the DNA molecule and therefore potential mutant 
samples. Homoduplexes (dsDNA with matching maternal and paternal strands) have different 
melting profiles to heteroduplexes (mismatched strands indicating mutation), allowing 
detection of heterozygous mutations, such as single nucleotide polymorphisms (SNPs). 
Samples with highly variant curves were sequenced via the Sanger method to confirm the 
presence of any potential mutations, and the nature of the mutation.  
Individual DNA samples (2 μl at 10 ng/μl) were pipetted into individual wells of an opaque 
96 well plate (4titude Framestar 96), for a final amount of 20 ng DNA. To each well 
containing DNA, the following reagents were added: 
Reagent Volume 
HotShot Diamond PCR Mastermix (Clent 
Life Sciences) 
5 μl 
LCGreen gene scanning reagent (Idaho 
Technologies) 
1 μl 
Sterile distilled H2O 2.8 μl 
Forward Primer (Alta Bioscience) 0.1 μl 
Reverse Primer (Alta Bioscience) 0.1 μl 
 
HotShot diamond PCR Mastermix contains an optimum mixture of MgCl2, PCR reaction 
buffer, dNTPs and Taq polymerase for the PCR reaction. This was performed for each ATM 
exon, and the primers used were at a concentration of 250 ng/μl throughout the study. Mineral 
oil (10 μl, Sigma) was added to overlay the reaction and PCR was performed to the following 
parameters (G-Storm GS1 Thermal Cycler, table over page): 
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Step Temperature Time 
1. Initial Denaturation 95 
o
C 2 min 
2. Denaturation 94 
o
C 30 sec 
3. Annealing X 
o
C 30 sec 
4. Homo/Heteroduplex 
Formation 
94 
o
C 30 sec 
5. Final Hold 25 
o
C ∞ 
 
X denotes the annealing temperature that differed according to the optimum primer annealing 
temperatures (see table S1 for information). Steps 2-3 were repeated 45 times.  
2.5 Primer annealing temperature optimisation 
 DNA (2 μl at 10 ng/μl) was added to individual wells of a 96-well plate (VWR). The same 
volumes of reagents as above were added to the DNA, and PCR was carried out using the 
same above parameters excluding the annealing temperature; annealing temperature gradients 
of 53-61 
o
C and 60-68 
o
C were set up (G-Storm GS1 Thermal Cycler, TECNE TC-512), so 
that the annealing temperatures would incrementally increase lengthways across 96-well 
plates. By setting up multiple PCR reactions for each exon all along the temperature gradient, 
the optimum annealing temperature could be obtained by analysing the products from each 
different annealing temperature. The successes of the PCR reactions were measured by the 
presence of a melting curve using a LightScanner (Fig 6A). Gel electrophoresis was also 
performed to check for product (fig. 6B). PCR product (10 µl) with 3 µl loading buffer was 
ran on a 2% agarose gel with Tris/borate/EDTA (TBE) buffer. DNA was stained with SYBR 
safe (Invitrogen), which intercalates between DNA bases and is excited by UV light. DNA 
bands were visualised using a UV lightbox (Syngene G-box). The annealing temperature that 
produced the largest amount of DNA product whilst not producing any non-specific product 
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was deemed to be the optimum annealing temperature for each primer. However, certain 
primers proved difficult to optimise (fig. 6). For “unclean” PCR reactions that contained non-
specific product, higher annealing temperatures were attempted. For those that produced little 
or no product and/or amplified a particularly large exon fragment, a wider range of annealing 
temperatures was attempted, and the annealing time was increased from 30s to 1m 30s. The 
number of PCR cycles was also increased from 45 to 60 for such samples. 
 
 
 
Figure 6 – Example of the primer optimisation technique, depicting ATM exon 26. A. Melting curves revealing the level of 
PCR product present at particular annealing temperatures. Note that there are two individual melts per curve rather than one 
smooth melt, indicating the presence of undesired PCR product.  B. Agarose gel showing product levels/annealing temperature. 
Note that at these annealing temperatures the primers were producing two bands in each lane, confirming the presence of non-
specific product. Exon 26 therefore required further optimisation.  
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2.6 Sequencing Analysis 
 Exons of interest were amplified using the Sanger method. The method involves the 
sequencing PCR reaction being carried out in the presence of both regular deoxynucleotides 
(dNTPs) and fluorescently labelled dideoxynucleotides (ddNTPs). Chain elongation proceeds 
until a ddNTP is inserted by DNA polymerase rather than a regular dNTP, which halts 
elongation. By chance, this will eventually occur for every base in the exon, producing DNA 
fragments of varying length ending with a fluorescently labelled nucleotide. The DNA is 
therefore sequenced based on the ascending order of size of DNA fragments, identified by the 
migration lengths on a capillary tube matrix, and detecting via laser which fluorescent 
nucleotide is present on each DNA molecule variant. 
Individual DNA samples (2 μl at 10 ng/μl) were loaded onto 96-well plates. To each well 
containing DNA, the following reagents were added:  
Reagent Volume 
TrueStart Buffer 
(Fermentas) 
2.5 μl 
MgCl2  (Fermentas) 2 μl 
dNTPs (Invitrogen) 0.2 μl 
Sterile distilled H2O 17 μl 
TrueStart Taq polymerase 
(Fermentas) 
0.3 μl 
Forward Primer 0.5 μl 
Reverse Primer 0.5 μl 
 
PCR was then carried out to the following parameters (Applied Biosystems GeneAmp PCR 
System 9700, table over page): 
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Step Temperature Time 
1. Initial 
Denaturation 
95 
o
C 4 min 
2. Denaturation 95 
o
C 30 sec 
3. Annealing X 
o
C 30 sec 
4. Extension 72 
o
C 45 sec 
5. Final Extension 72 
o
C 7 min 
 
X denotes the annealing temperature that differed according to the optimum primer annealing 
temperatures. Steps 2-4 were repeated 37 times. To purify the amplified exon regions, 2 μl 
ExoSap (Affymetrix) was added to wells of a fresh 96-well plate, to which 2.5 μl PCR 
product was added. This was then heated to 37 
o
C for 15 minutes and 80 
o
C for a further 15 
minutes. The following reagents were added to the DNA/ExoSap product: 
BigDye buffer (Applied 
Biosystems) 
3.5 μl 
BigDye reagent (Applied 
Biosystems) 
1 μl 
Forward or reverse 
Primer 
0.3 μl 
Sterile distilled H2O 14.7 μl 
 
BigDye contains the optimum mixture of dNTPs, fluorescently labelled dideoxynucleotides 
and DNA polymerase for the reaction. PCR was then carried out to the following parameters 
(table over page): 
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Step Temperature Time 
1 96 
o
C 2 min 
2 96 
o
C 10 sec 
3 50 
o
C 5 sec 
4 60 
o
C 4 min 
 
Steps 2-4 were repeated 25 times. Pure ethanol (50 μl) with 4% sodium acetate was added to 
the PCR products and incubated at room temperature for 45 minutes. The plate was then span 
at 1500 g for 20 minutes and the supernatant removed. Ethanol (70%, 100 μl) was then added 
to the wells and the plate span at 1500 g for 12 minutes. The supernatant was removed and the 
DNA left to air dry at room temperature for 1 h. 10 μl HiDi Formamide (Applied Biosystems) 
was added to each well and the plate heated to 99
o
C for 5 minutes before rapid cooling on ice. 
The DNA/HiDi formamide solution was transferred to a 96-well sequencing plate (Applied 
Biosystems) and the DNA sequenced (Applied Biosystems/ Hitachi 3130XL 16 Capillary 
DNA Sequencer). Mutant exon sequences were identified by comparison with confirmed WT 
sequences obtained by the same method. For further confidence, such sequences were also 
compared for sequence similarity against the online human genomic database using the 
National Center for Biotechnology Information Basic Local Alignment Search Tool (NCBI 
BLAST, National Library of Medicine, USA). 
2.7 Cell culture and cytotoxicity assays 
 Human B-CLL CII and MEC-1 isogenic cell lines were previously stably transfected with 
ATM shRNA. Green fluorescent protein (GFP) shRNA was also stably transfected into both 
cell lines as a negative control (Table S3). Cells were maintained in RPMI 1640 media with 
added glutamine (Invitrogen), containing 10% foetal calf serum (PAA) and 0.5% Penstrep 
(Invitrogen). Triplicate assays were performed in 96-well tissue culture plates (Corning). 
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Cells were seeded at a density of 1x10
5
/200 µl. All drugs were resuspended in DMSO. 
Olaparib (AstraZeneca) was added to wells at concentrations of 1 μM, 3 μM and 10 μM along 
with untreated control wells. The cells were incubated at 37 
o
C and 5% CO2 for 48h before the 
addition of the following concentrations and types of HDACi to untreated cells and the 
varying concentrations of olaparib: 
Drug CII Mec-1 
Valproic Acid (VPA, Sigma) 1, 2.5, 5, 10 mM 1, 2, 3, 4 mM 
Vorinostat (suberoylanilide 
hydroxamic acid - SAHA, Sigma) 
1, 2.5, 5, 10 µM 1, 2.5, 3.5, 5 µM 
Belinostat (PXD-101, Sigma) 1, 2, 3, 4 µM 1, 2, 3, 4 µM 
 
 The cells were incubated for a further 120 hours. After incubation, the cells were equilibrated 
to room temperature for 30 minutes. Cell TiterGlo (Promega) was used to assay for viable 
cells, which gives a quantifiable luminescent signal based on the levels of ATP present. The 
amount of ATP linearly correlates closely with the amount of viable cells present. 50 μl Cell 
TiterGlo was added to the wells, which were placed on an orbital shaker at 100 RPM for 10 
min to induce cell lysis. The luminescence levels were analysed (Wallac Victor
2
 1420 
Multilabel Counter) and the surviving fractions quantified relative to the luminescence levels 
of the untreated controls.  
2.8 Western Blotting 
 Both ATM and GFP knockdown (KD) CII and MEC-1 cells were lysed with 100 ml UTB 
buffer containing 9 M Urea, 150 mM β-mercaptoethanol and 50 mM Tris. A 6% 
polyacrylamide gel was prepared with the following reagents (table over page):  
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Reagent Volume 
Sterile distilled H2O 27.4 ml 
1M Tris/ 1M Bicine Buffer 4 ml 
30% Acrylamide (BioRad) 8 ml 
10% sodium dodecyl sulfate (SDS) 400 µl 
 Tetramethylethylenediamine 
 (TEMED, Sigma) 
80 µl 
10% Ammonium persulfate (APS) 200 µl 
 
Running buffer was composed of dH2O with 10% 1 M Tris/1 M Bicine Buffer and 0.1% 
SDS. 15 µl cell lysate was loaded with 5 µl loading buffer, composed of 30% glycerol, 10% 
SDS, 0.02% bromphenol blue and 2% 2-mercaptoethanol in dH2O. The gel was ran at 25 mA 
for 5 hours. The transfer buffer contained 5600 ml sterile distilled H2O, 1400 ml methanol 
(Sigma), 203 g Glycine (Sigma) and 40.6 g Tris (Sigma), and the gel was transferred onto 
nitrocellulose membrane at 200mA for 16 hours.  Proteins were visualised on the 
nitrocellulose membrane with ponceau stain, comprised of 1 l dH2O, 10 g Ponceau S and 30 g 
trichloroacetic acid. Membranes were washed in Tris-buffered saline - Tween (TBS-T) 3 
times for 5 minutes and blocked for 2 hours in 5% dried milk/TBS-T. Washes were repeated 
and the membranes probed for total ATM using monoclonal mouse antibody (Calbiochem, 
1:250) and total SMC-1 using polyclonal antibody (Bethyl, 1:5000), a downstream target of 
ATM, as a loading control. Primary antibodies were diluted in 5% bovine serum albumin 
(BSA) in TBS-T. Washes were repeated and the membranes incubated with secondary 
horseradish peroxidise (HRP)-conjugated antibody for 1 hour. Mouse α ATM (Dako) was 
diluted 1:1000 and rabbit α SMC-1 (Bethyl) at 1:3000 in 5% dried milk/TBS-T. ECR reagent 
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was prepared immediately prior to use by mixing substrate (Millipore) and hydrogen peroxide 
(Dako) in a 1:1 ratio.  
2.9 Visualisation of Rad-51 intra-nuclear foci by immunofluorescence staining 
 CII cell lines with stable GFP and ATM knockdown were treated with 3 µM vorinostat and 
DMSO as a negative control, and were irradiated with 2 Gy of ionising radiation (IR). The 
cells were then placed into ice-cold extraction buffer for 5 minutes. The extraction buffer was 
comprised of: 
Reagent  Volume (250ml total in dH2O) 
10mM piperazine-N,N′-
bis(2-ethanesulfonic 
acid) (PIPES) 
0.81 g 
300mM sucrose 25.67 g 
20mM NaCl 1 ml of 5 M stock 
3mM MgCl2 6 ml of 500 mM stock 
0.5% Triton X-100 1.25 ml 
 
The cells were then fixed with 3.6% paraformaldehyde in PBS at timepoints of 0, 1, 8 and 24 
hours after radiation exposure for 10 minutes. The cells were washed in DPBS 3 times for 5 
minutes and blocked using 10% FCS in DPBS for 12 hours. Individual samples were stained 
with the following antibodies (Table over page): 
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1
o
 Antibody 2
o
 Antibody 
Mouse monoclonal α γH2AX (Millipore, 
1:1000) 
α Mouse Alexa 488 (Invitrogen, 1:400) 
Rabbit α Rad51 (Santa Cruz 
Biotechnology, 1:50) 
α Rabbit Alexa 488 (Invitrogen, 1:400) 
 
A488 was used for both samples because different cell samples were stained for RAD51 and 
γH2AX. Antibodies were diluted in 1% FCS in DPBS, and incubated for 1 hour at RT. 
Samples were stained in suspension with 1
o
 antibody, washed three times in DPBS for 5 
minutes then stained in suspension with 2
o
 antibody. 
2.10 Slide preparation, mounting and microscopy 
 Microscope slides were washed in 70% ethanol/1% HCl for 1 hour and washed 3 times for 
20 minutes in dH2O before being left to dry overnight at 37
o
C. 20 µl poly-L-Lysine (Sigma) 
was carefully spread onto each well and left to dry for 20 minutes at RT. Slides were washed 
with dH2O for 5 seconds and left to dry at 37 
o
C for 20 minutes. Cell suspension was added to 
wells of the slides and left to adhere for 45 minutes in dark conditions, then aspirated off and 
the slides left to dry for 10 minutes at RT in dark conditions. VECTAshield (20 µl) with 4',6-
diamidino-2-phenylindole (DAPI, Vector Laboratories) was added to the wells before a glass 
coverslip was placed over the slide and left to dry for 20 minutes in dark conditions. Rad51 
and γH2AX foci analysis was carried out using a Nikon Eclipse E600 Fluorescence 
Microscope and a 60x Plan Fluor objective.  Images were captured and rendered using 
Hamamatsu C4742-95 Digital Camera and Volocity 3D Image Analysis software. Images of 
RAD51 and γH2AX staining were exposed for 2.5 seconds.  
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2.11 Data Analysis 
 Student’s two-tailed T tests were carried out on the means of three triplicate assays for each 
cell line differing in HDAC inhibitor treatment and ATM status. The effects of both drugs 
alone were compared with both in combination. Each dose combination was also compared 
between WT GFP knockdown control cells and ATM knockdown cells.  Drug synergy was 
assessed by obtaining Combination Index (CI values) for each drug dose using CalcuSyn 
(Biosoft) software. Student’s 2-tailed T tests were also used to compare Rad51 positivity 
between untreated or 3 µM vorinostat treated cells as well as ATM knockdown and WT GFP 
knockdown control cells. 
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3.0 Results 
 
 
3.1 Detection of ATM null B-CLL tumours 
Initially, a cohort of 28 B-CLL patient tumours was first screened for potential ATM 
mutations using Hi-Res Melting. Initial PCR reactions were unsuccessful (fig. 7A), and to 
rectify this, the purity of the DNA samples was increased and the consistency of DNA sample 
concentration was confirmed at 10 ng/µl (see section 2.3). All PCR reagents were replaced 
Figure 7 – Initial Hi-Res Melting problems. A. Example of failed melting curves that were originally observed due 
to lack of product. B. A map of the 96-well plate showing relative fluorescence levels and therefore product levels. 
Blue/green = low fluorescence; yellow/red = high fluorescence. The example provided shows three exons with 
identical optimum annealing temperatures amplified on the same 96-well plate. Exon 10 was being amplified 
successfully, while exon 7 and 35 failed to produce any product. 
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excluding primers, but the same reaction volumes were maintained because these had been 
previously optimised and were known to be correct. This resulted in some improvement, but 
there was a consistent pattern of single exons producing product while others did not (fig. 7 
B). It was therefore suspected that either the primers were not functioning properly or that the 
optimum primer annealing temperatures were incorrect. Thus, a revised set of primers for all 
ATM exons was ordered and annealing temperature optimisation was carried out on primers 
with amended sequences (see section 2.5/table S1).  The optimum annealing temperatures for 
several new primers was established (table S1). 
However, some primers proved to be difficult to optimise in the time available. Hi-Res 
melting mutational analysis was therefore resumed using the new primers and the new 
optimum annealing temperatures that had been confirmed, but many of these PCR reactions 
were still consistently failing. It was decided that curve variants of the exons that had worked 
would be sequenced, with the intention of sequencing samples with variant curves to assess if 
any mutations were indeed present (fig. 8A). 
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Figure 8 – Hi-Res Melting results. A. Table illustrating exons successfully analysed using H-Res Melting. Green 
indicates a normal melting curve; red indicates a variant curve that was sequenced to check for mutation. B. Graph 
depicting changes in melting curves of exon 62, with the variant curves of PICCLE GB and PICCLE IM tumours 
indicated (green). C. The homozygous SNP detected in the DNA fragment amplified by exon 62 primers of PICCLE 
IM compared with the WT sequence of PICCLE GB.    
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3.2 ATM exon sequencing 
ATM exon samples that were flagged as potential mutants via Hi-Res melting were next 
sequenced (fig. 8 A, B). Surprisingly, only one sequence change was identified. A 
homozygous single nucleotide polymorphism (SNP) was identified in the PICCLE IM sample 
at c.8786+8A>C (Fig. 8 B, C), a non-coding intronic change. The change was located 8 
nucleotides downstream of exon 62, which potentially could have been influential on ATM 
function because exon 62 lies within the C-terminal section of ATM, which contains the PI3 
kinase domain along with its regulatory domains (fig.1). Mutations so close to exons often 
cause splicing problems. Interestingly, this particular SNP had been found to be relatively 
common in incidences of childhood T-lineage acute lymphoblastic leukaemia (T-ALL), and 
had been previously investigated by other groups (Gumy-Pause et al., 2006; Meier et al., 
2006). However, these papers reported that no ATM mRNA splicing defects could be 
confirmed using reverse transcriptase (RT) PCR or DNA sequencing. It was therefore 
concluded that this SNP did not have an effect on the function of ATM, and it was decided to 
stop searching for ATM mutant patients and establish whether PARP inhibitors could 
sensitise B-CLL tumour cell lines, CII and MEC-1, to HDAC inhibitors. 
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3.3 Cytotoxic effects of combined PARPi/HDACi treatment – validations and assay 
optimisation 
 
The effectiveness of ATM knockdowns in CII and MEC-1 cells were verified via western 
blot. No ATM band could be observed in MEC-1 cells treated with ATM shRNA indicating a 
highly efficient knockdown. Residual ATM protein expression was detected in ATM shRNA 
treated CII cells, however, although the band observed was markedly fainter than GFP 
shRNA treated WT control cells (fig. 9B).  
 PARP and HDAC inhibition on CII and MEC-1 isogenic B-CLL cell lines were next 
analysed (See table S2 for cell line details). Previously studied concentrations of 1, 3 and 
10µM were used because these values had previously produced an effect, but the doses of all 
three HDAC inhibitors had to be optimised on both CII and MEC-1 cells to obtain a viable 
Figure 9 – Dose response optimisations and knockdown validation western blot. A. Example of HDACi dose 
optimisation. The top graph indicates the first concentrations of belinostat that were used on WT CII cells, and the 
resulting response. At concentrations above 6 µM all cells were killed, and the doses were lowered to produce an 
appropriate response as seen in the lower graph.  This procedure was necessary for all HDAC inhibitors tested in both cell 
lines. B.  Western blot to validate loss of ATM protein in cells treated with ATM shRNA. SMC1, a downstream effector 
of ATM, was used as a loading control. 
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dose response curve (fig. 9A). This process involved obtaining a starting figure from previous 
studies that had used the compound in cytotoxicity assays and further optimising the dose for 
the B-CLL cell lines. It was also noted that the concentrations of olaparib used were not 
inducing high levels of cytotoxicity. However, the concentrations of olaparib were not altered 
for a number of reasons. Firstly, previous studies had confirmed that 10 µM olaparib was a 
high enough concentration to inhibit all PARP1 activity in similar assays with B-CLL cell 
lines (Weston et al., 2010). Secondly, concentrations of olaparib above 10 µM are likely to 
induce off-target effects on cells not related to the role of PARP1 in the DDR. Poly(ADP-
ribosyl)ation is a widespread cellular process, and high doses of PARP inhibitor are 
increasingly likely to disrupt this function to a point at which many other cellular processes 
other than the DDR are affected (Weston et al., 2010).  Finally, the aim of the study was to 
investigate synergy between PARPis and HDACis rather than the effects of olaparib alone, 
and olaparib having a low effect may have caused any HDACi synergism to be more 
apparent. 
3.4 Olaparib in combination with valproic acid 
The first HDAC inhibitor that was assessed was valproic acid (VPA), as it had previously 
been shown to synergise with olaparib (Weston et al., 2010). VPA is a small molecular weight 
carboxylate compound, and inhibits the catalytic activity of class I and II HDACs, although 
more specifically class I (Lagace and Nachtigal, 2004). VPA has undergone promising trials 
in cervical cancer patients as well as acute myeloid leukaemia (AML) and myelodysplastic 
syndrome (MDS) both as monotherapy and in combination with other chemotherapeutics 
(Federico and Bagella, 2011). 
Firstly, both ATM WT (GFP KD control) and ATM KD CII cells responded fairly similarly 
to olaparib and VPA alone. Both WT and ATM KD CII cells did not respond strongly to 
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olaparib treatment, and ATM deficient cells were not significantly more sensitive to olaparib 
(fig. 10A). At 10 µM, the surviving fraction of WT cells was 0.69, and 0.8 in ATM deficient 
cells. Both WT and ATM deficient cells responded to VPA alone, with a surviving fraction of 
0.16 and 0.19 respectively when 10 mM VPA was administered. Generally, higher doses of 
VPA resulted in lower surviving fractions, although, 2.5 mM VPA alone was observed to 
increase the proliferative capacity of ATM deficient cells.  Surprisingly, CII WT cells 
appeared more sensitive to the same doses of VPA than ATM deficient cells, and consistently 
showed a lower surviving fraction than ATM KD cells for the same corresponding dose of 
VPA (fig. 10A). This observation was statistically significant for 5 mM and 10 mM VPA in 
combination with any olaparib dose (P<0.05).  
The combination of olaparib with VPA had an additive cytotoxic effect on the surviving 
fractions as the dose of each drug was increased for both WT and ATM deficient cells. 
Generally, VPA combined with olaparib had a pronounced killing effect compared with 
olaparib alone in both WT and ATM deficient cells, a trend that was observed throughout the 
CII cell lines as olaparib had such a minimal effect. Interestingly in this case, compared to 
WT cells, ATM KD cells had more incidences whereby VPA in combination with olaparib 
had a significant killing effect compared with VPA alone – for example, all three doses of 
olaparib had a cumulative effect on the effectiveness of 5 mM VPA. However, lower doses 
did not produce such significant effects (fig. 10A). 
To quantify any potential drug synergy, the data was then analysed using CalcuSyn. In WT 
cells, 1 and 3 µM olaparib were synergistic with 1mM VPA, and all doses of olaparib were 
synergistic with 10 mM VPA (fig. 10B). A different picture for ATM deficient cells was 
observed; generally, lower doses of VPA were more synergistic with lower doses of olaparib 
while 10 mM VPA was mildly antagonistic (fig. 10B). This was interesting because ATM 
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deficient cells were synergising at lower doses where off-target effects were less likely to be 
occurring. However, there was little difference in surviving fraction between WT and ATM 
deficient cells in these lower doses, and the observed synergy may have been a result of the 
HDAC inhibitor alone not affecting ATM deficient cells as much as WT cells. Thus, WT cells 
were generally more sensitive to HDAC inhibitors overall and the differences in surviving 
fraction between the WT and ATM cells were not very great. It was therefore difficult to 
conclude that PARP and HDAC inhibitors synergised more in ATM knockdown cells. 
The p53-mutant MEC-1 cells reacted in surprising ways to the drugs. Firstly they were more 
sensitive to VPA in general and lower concentrations had to be used than with CII cells (fig. 
10A). In both ATM WT and ATM KD cells olaparib alone seemed to have an overall positive 
effect on cell proliferation. The same phenomenon was observed with 1 and 2 mM VPA, both 
alone and in combination with 1, 3 and 10 µM olaparib (fig. 10A). Higher concentrations of 
olaparib actually resulted in a higher proliferative effect in combination with 1, 2 and 3 mM 
VPA in ATM deficient cells, while the effect was especially pronounced in WT cells at 1 mM 
VPA. In WT cells, killing effects were observed with 3 and 4 mM VPA alone and in 
combination with olaparib, but no significant additive effect was observed with higher 
concentrations of olaparib. However, in ATM deficient cells, only 4 mM VPA resulted in any 
significant killing, and it was also observed that ATM deficient cells seemed to be more 
resistant to VPA than WT cells as seen in CIIs.  Due to these unexpected observations, and 
that the CalcuSyn program requires an olaparib dose response curve, synergism values for 
olaparib and VPA treatment in MEC-1 cells could not be obtained. 
From this evidence, it was difficult to conclude that ATM deficient cells were more sensitive 
to the combination of olaparib and VPA. The data for the p53 mutant MEC-1 cells was also 
inconclusive due to a lack of synergism data. However, it was clear that lower doses of 
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HDAC inhibitor had an increased proliferative effect on the MEC-1 cells, and that MEC-1 
cells were generally more sensitive to HDAC inhibitor meaning that lower doses had to be 
used. Also, it was clear that WT cells were more sensitive to HDAC inhibitors than ATM 
deficient cells independent of p53 status. To verify these observations, the combined 
effectiveness of olaparib with a different HDAC inhibitor, vorinostat, was assessed. 
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Figure 10 - The effects of olaparib and VPA on CII and MEC-1 isogenic B-CLL cell lines. A. Dose response analysis for 
olaparib + valproic acid treatment responses of ATM WT (GFP KD control) and ATM KD CII and MEC-1 Cell lines.† = 
olaparib/HDAC inhibitor dose statistically significant relative to untreated control (P < 0.05, †† = P < 0.01). + = 
combined olaparib and HDAC inhibitor dose statistically significant relative to olaparib dose alone (P < 0.05, ++ = P < 
0.01). × = combined olaparib and VPA dose statistically significant relative to VPA dose alone (P < 0.05, ×× = P < 0.01). 
n = 3, error bars represent standard error of the mean. B. Synergism ratings for each combined dose of olaparib + valproic 
acid in CII cell line. +++ = strongest synergy, ± = very minor synergy/antagonism, --- = strongest antagonism. 
 
A
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3.5 Olaparib in combination with vorinostat 
The small molecule pan-HDAC inhibitor vorinostat (Federico and Bagella, 2011) was next 
assessed for synergy with the PARPi olaparib in ATM deficient B-CLL tumour cell lines. 
Vorinostat was used because it has undergone phase II clinical trials and been approved for 
treatment of refractory cutaneous T-cell lymphoma (CTCL) in the US (Marks and Breslow, 
2007). 
 Again in CII cells, olaparib had a minimal and similar effect on both WT and ATM KD cell 
lines (fig. 11A). As expected, increasing doses of vorinostat resulted in decreasing surviving 
fractions in WT cells. However, once again ATM deficient cells were less affected by the 
same doses of HDAC inhibitor than WT cells – concentrations of 5 and 10 µM vorinostat at 
any combination produced significantly lower surviving fractions in WT cells (P<0.05). In 
ATM deficient cells, vorinostat alone actually had a greater cytotoxic effect at 1µM than at 
concentrations of 2.5 and 5 µM (fig. 11A). 10 µM vorinostat resulted in more substantial 
killing, reducing the surviving fraction to 0.5, but this was high compared to 0.14 as observed 
in WT cells treated with 10 µM vorinostat.  
The combination of olaparib with vorinostat produced some interesting trends. In both WT 
and ATM deficient cells, 1 µM and 3 µM olaparib did not produce a statistically significant 
effect on the efficacy of vorinostat at concentrations of 1 and 2.5 µM compared to vorinostat 
alone, while 5 µM vorinostat produced a statistically significant but overall minor effect with 
these olaparib doses in WT cells but not ATM deficient cells (fig. 11A). At 2.5 µM, the 
surviving fraction in WT cells was even higher in combination with 1 and 3 µM olaparib, and 
this was also observed in ATM deficient cells with 1 µM olaparib. 10 µM olaparib caused an 
obvious additive effect in both cells of differing ATM status. 
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The synergism data for CII cells suggested that WT cells were more synergistic at higher 
levels of vorinostat, although mild synergism was observed in 1 µM olaparib combined with 
1µM vorinostat (fig. 11B). This was also observed in ATM deficient cells, but 1 and 3 µM 
olaparib were also shown to be highly synergistic with 1 µM vorinostat, although strangely 
1µM was antagonistic. 2.5 µM vorinostat with 1 and 3 µM olaparib was seen to be 
antagonistic in ATM deficient cells, reflecting the observation that the surviving fraction of 
cells treated with 2.5 µM vorinostat increased when combined with 1 µM olaparib relative to 
vorinostat alone.  In general, both WT and ATM deficient cells showed olaparib/vorinostat 
synergy at many doses. Thus as with VPA, it was difficult to conclude that ATM deficient 
cells were more sensitive to combined treatment of olaparib and vorinostat, and it was even 
more evident in this case that WT cells were more sensitive to vorinostat than ATM deficient 
cells. 
Similarly to the previous experiments with VPA, the p53 mutant MEC-1 cells were more 
sensitive to vorinostat and reduced doses had to be used. Again, olaparib did not exhibit a 
killing effect on MEC-1 cells and actually resulted in higher proliferation with increasing 
olaparib doses in both WT and ATM deficient cells. Thus again, it was not possible to obtain 
synergy ratings for olaparib and vorinostat in MEC-1 cells. As observed with VPA, low levels 
of vorinostat (1 µM, and 2 µM to a lesser extent in ATM deficient cells) unexpectedly 
resulted in a substantial increase in proliferation regardless of ATM status. At concentrations 
above 1 µM, vorinostat induced very high levels of killing in ATM WT cells, while 
contrastingly in ATM deficient cells only 3.5 µM and 5 µM resulting in any significant 
cytotoxicity. Due to this aberrant and unexpected behaviour of the MEC-1 cells, it was not 
possible to optimise the correct HDAC dose to provide reliable dose responses in both cells of 
differing ATM status. 
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Similar cytotoxicity patterns across CII and MEC-1 cells were observed with vorinostat as 
were also observed with VPA. It was not possible to conclude that olaparib and vorinostat 
resulted in more synergy in CII ATM knockdown cells. Again, p53-mutant cells showed an 
increased proliferative effect at low doses of HDAC inhibitor, and also were more sensitive in 
general thus requiring a lower dose range. In both cell lines, WT cells were clearly more 
sensitive overall to HDAC inhibition. The next step was to assess the effects of olaparib and a 
third HDAC inhibitor, belinostat. 
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Figure 11 - The effects of olaparib and vorinostat on CII and MEC-1 isogenic B-CLL cell lines A. Dose response 
analysis for olaparib + vorinostat treatment responses of ATM WT (GFP KD control) and ATM KD CII and MEC-1 
Cell lines.† = olaparib/vorinostat inhibitor dose statistically significant relative to untreated control (P < 0.05, †† = P < 
0.01). + = combined olaparib + vorinostat inhibitor dose statistically significant relative to olaparib dose alone (P < 0.05, 
++ = P < 0.01). × = combined olaparib + vorinostat dose statistically significant relative to vorinostat dose alone (P < 
0.05, ×× = P < 0.01). n = 3, error bars represent standard error of the mean. B. Synergism ratings for each combined dose 
of olaparib + vorinostat in CII cell line. +++ = strongest synergy, ± = very minor synergy/antagonism, --- = strongest 
antagonism. 
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3.6 Olaparib combined with belinostat 
The final HDAC inhibitor that was analysed was belinostat, another small molecule pan-
HDAC inhibitor also primarily targeting class I and II HDACs (Federico and Bagella, 2011). 
Belinostat has also been approved for and undergone clinical trials for the treatment of several 
haematological malignancies and solid tumours, showing good patient tolerance and 
promising anticancer activity (Federico and Bagella, 2011). 
 Both CII cell types responded to olaparib alone minimally across 1 and 3 µM, but a larger 
drop in surviving fraction was this time observed in WT cells from 3 to 10 µM, from 0.96 to 
0.88 in ATM deficient cells and 0.94 to 0.69 in the control cells (fig. 12A). It was again very 
difficult to optimise the dose of belinostat for CII cells, due to the large differences in dose 
response observed between cells of differing ATM status - again, the viability of WT cells 
was compromised more than ATM deficient cells. 3 and 4 µM belinostat resulted in 
significantly reduced surviving fractions in WT cells compared to ATM cells (P<0.05). 
Combining belinostat with olaparib did not result in any statistically significant changes 
relative to belinostat alone in WT cells, and more pronounced losses in surviving fraction 
with all doses of belinostat were observed with 10µM olaparib than the lower doses (fig.12A). 
In ATM deficient cells, lower doses of HDAC inhibitor did not produce dramatic additive 
effects with 1 and 3 µM olaparib, but higher doses of 3 and 4 µM belinostat had a more 
pronounced additive effect. With 10 µM olaparib, all concentrations of belinostat resulted in 
visibly reduced surviving fractions in comparison to belinostat alone, which was also seen in 
the WT cells. Again, the dose responses were similar in pattern across both cells of differing 
ATM status, with the exception that ATM KD cells were far more resistant to HDACi 
induced cytotoxicity. CalcuSyn was again used to analyse the data and establish any possible 
synergy that was occurring. 
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Synergism values indicated that in WT cells, 10 µM olaparib synergised with all doses of 
belinostat, and all doses of olaparib were synergistic with 4 µM belinostat (fig. 12B). 3 µM 
belinostat with 3 µM olaparib was also synergistic. In ATM deficient cells, 1, 2 and 3 µM 
belinostat was synergistic with 10 µM olaparib and 3 µM belinostat was synergistic with all 
olaparib doses. However, lower doses of olaparib combined with belinostat were highly 
antagonistic, reflected in the fact that 1 and 2 µM doses of belinostat actually increased the 
surviving fraction relative to the untreated control, or treated with 1 and 3 µM olaparib (fig. 
12B). This was encountered because the HDACi induced killing effects between WT and 
ATM deficient cells were so different, and it was very difficult to obtain viable dose 
responses with the same doses on cells of differing treatment. As with the other HDAC 
inhibitors, there was little evidence for increased synergy between olaparib and belinostat in 
ATM deficient cells. 
The p53-mutant MEC-1 cells responded to the drugs similarly to previous experiments, and 
thus it was very difficult to use the data to gain insight into drug synergy. Regardless of ATM 
status, olaparib once again had an overall positive effect across 10µM and it was again 
therefore not possible to calculate accurate synergism values due to the constraints of the 
CalcuSyn program (fig. 12A). Low doses of belinostat (1 µM) again resulted in increased 
proliferation in both cells, which was reduced with the addition of olaparib. WT cells were 
more susceptible to belinostat doses above 1µM than ATM deficient cells, in which additive 
killing could be observed as the doses of olaparib and belinostat increased, but the fact that 
the control cells were almost completely killed by doses higher than 1 µM meant that no 
sound conclusions could be drawn from the dose response data in MEC-1 cells.  
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Figure 12  - The effects of olaparib and belinostat on CII and MEC-1 isogenic B-CLL cell lines A. Dose response analysis 
for ATM WT (GFP KD control) and ATM knockdown CII and MEC-1 cells.† = olaparib/belinostat inhibitor dose 
statistically significant relative to untreated control (P < 0.05, †† = P < 0.01). + = combined olaparib + belinostat inhibitor 
dose statistically significant relative to olaparib dose alone (P < 0.05, ++ = P < 0.01). × = combined olaparib + belinostat 
dose statistically significant relative to vorinostat dose alone (P < 0.05, ×× = P < 0.01). n = 3, error bars represent standard 
error of the mean. B. Synergism ratings for each combined dose of olaparib + belinostat in CII cell line. +++ = strongest 
synergy, ± = very minor synergy/antagonism, --- = strongest antagonism. 
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3.7 Common observations 
 Several common themes were observed across all cytotoxicity experiments with different 
HDAC inhibitors. Firstly, the concentrations of olaparib used did not have a significant 
cytotoxic effect on ATM deficient cells as previously observed. Olaparib had a marginal 
effect at 10 µM in CII cells, while in p53 mutant MEC-1 cells an increased proliferative effect 
was often observed rather than any cytotoxic effects at all, an effect that prevailed regardless 
of ATM status. The concentrations of olaparib used were kept constant, however, for reasons 
previously detailed.   
It was also observed that HDACis had a more pronounced effect on WT cells than ATM 
deficient cells, with this effect having statistical significance at higher doses of HDAC 
inhibitor in CII cells. The same was observed in the p53 mutant MEC-1 cells although this 
was not statistically significant. MEC-1 cells also exhibited large increases in proliferation at 
very low doses of HDACi, but were significantly more sensitive to HDACis than CII cells 
overall - the surviving fraction rapidly dropped as the HDACi dose increased past the dose 
that induced proliferation. PARPis and HDACis were often shown to synergise in ATM 
deficient cells at various combinations of different concentrations of each drug. However, the 
same was often observed in WT cells, and coupled with the fact that WT cells were more 
sensitive to HDACis than ATM KD cells, it could not be comprehensively concluded that 
ATM defective B-CLL is selectively sensitised to HDACis by PARPis.  
3.8 Mechanisms behind observations 
To offer insight into the results observed in these experiments, the next step of the project was 
to establish if ATM dependent HR mechanisms were indeed compromised in cells treated 
with ATM shRNA. The effect of HDAC inhibition on these mechanisms was also analysed. 
To achieve this, both WT and ATM knockdown CII cells were exposed to ionising radiation 
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(IR) and immunostained for Rad51 foci formation. Rad51 is a DNA repair protein that is 
involved primarily with HR. In the event of DNA DSBs, Rad51 colocalises with and forms 
foci at the sites of the damage and modulates the recombinational repair of the breaks through 
homology sequence searching and strand invasion (Shaheen et al., 2011). Rad51 recruitment 
is dependent upon phosphorylation via the non-receptor tyrosine kinase c-abl in an ATM and 
DNA-PKcs dependent manner (Yuan et al., 2003). Thus, by quantifying the levels of Rad51-
positive cells of differing shRNA and HDACi treatment, the presence of active HR can be 
assayed for and some insight may be gained as to why the cells reacted to PARPi and HDACi 
so unexpectedly. If HR was still active in ATM deficient cells, they would not be vulnerable 
to PARP inhibition as observed in previous experiments (Weston et al., 2010)  because the 
unrepaired SSBs that turn to DSBs upon DNA replication would be repaired.   
For this experiment, CII cells were used. This was because they produced the most legitimate 
dose response curves. Also, it was decided that p53 WT cells would be used for simplicity, as 
due to time constraints it was unlikely that Rad51 foci induction in both cell lines could be 
analysed. 3 µM of the pan-HDAC inhibitor vorinostat was used to treat the cells because 
reliable dose responses were shown in CII cells treated with vorinostat, and 3 µM was deemed 
a high enough dose to have an effect whilst also keeping any off-target effects to a minimum. 
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3.9 The effects of ATM knockdown and HDAC inhibition on HR 
Firstly, as a positive control for cell labelling and the presence of DSBs, cells were stained for 
the DNA damage marker γH2AX. γH2AX is the phosphorylated form of histone H2AX, and 
is a rapidly induced biomarker of DNA DSBs. ATM is a principal mediator of γH2AX foci 
formation along with ATR and DNA-PKcs, but loss of ATM results in delayed resolution of 
γH2AX foci rather than a lack of γH2AX altogether (Wang et al., 2005). Immediately after 
irradiation very few γH2AX positive (5 or more foci) cells were observed, but at 1 hour post 
irradiation all samples, including ATM knockdown cells, showed 90-100% γH2AX positivity 
allowing for confidence that the staining protocol was effective and 2 Grays of IR was enough 
to reliably inflict DNA DSBs on the cells sampled (fig. 13A).  
After the staining control was confirmed, the levels of Rad51 positive cells were assessed for 
each sample to quantify the relative levels of HR DSB repair in GFP shRNA (ATM WT), 
ATM shRNA and/or HDACi treated cells. Cells were analysed at 0, 1, 8 and 24 hours post IR 
treatment. Cells were classed as Rad51 positive if the cell contained five or more intra-nuclear 
Rad51 positive foci (fig. 13B).  
Generally, Rad51 positive cells were shown to increase in proportion as the time after IR 
exposure lengthened (fig. 13C). For cells not treated with HDACi, the proportion of Rad51 
positive ATM KD cells was significantly lower across 1 h, 8 h, and 24 h timepoints than in 
WT untreated cells (fig. 13C). The most striking reductions were observed 1 hour after IR, 
where the proportion of Rad51 positive cells in ATM KD cells was only 9.4% compared to 
42.2% observed in WT cells. There was also a reduction at 8 hours post IR, from 50.7% in 
WT cells to 31.8% in ATM KD cells, while at 24 hours post irradiation 55% in WT cells were 
positive compared to 43.5% in ATM KD cells (fig. 13C). These data suggest that ATM 
knockdown results in diminished Rad51 foci formation, particularly at 1 hour after the 
 53 
 
occurrence of DSBs.  There was still a relatively high proportion of Rad51 positive cells by 
24 hours, however, suggesting that HR was not fully compromised.  
Although 3 µM vorinostat appeared to result in marginally lower proportions of Rad51 
positive cells across all timepoints in ATM deficient cells, this observation was not 
statistically significant. In WT cells however, a significant reduction was observed in HDACi 
treated cells at 0 and 1 hour after irradiation. At 0 hours post IR 10.1% of untreated WT cells 
were Rad51 positive, while 3.41% were observed in WT cells treated with vorinostat, and at 
1h post IR the difference was 42.2% compared with 23.9%.  These data support the idea that 
HDACs have some involvement in HR, particularly in the early onset of Rad51 foci. Again, 
however, a significant proportion of cells were still Rad51 positive at later time points in all 
samples, regardless of shRNA or HDAC inhibitor treatment.  
In conclusion, the information obtained in these experiments indicates that HR was not fully 
compromised in cells treated with ATM shRNA, which agrees with the observation that 
residual ATM protein was detected in CII cells (fig. 9B). Significant reductions are observed 
only in early timepoints, and while an overall reduction in Rad51 positive cells was observed 
in ATM shRNA and/or vorinostat treated cells, the extent of reduction was not enough to 
indicate severely impaired HR mechanisms. These revelations also may explain why ATM 
knockdown cells were not increasingly sensitive to PARP and/or HDAC inhibition.  
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Figure 13 – The effects of ATM knockdown and HDAC inhibition on homologous recombination in CII cells. A. Example 
images of γH2AX staining for 0 and 1h post IR treatment. Strong γH2AX foci formation was observed at 1h post IR in 
samples indicating the presence of DSBs throughout cell sample populations. B. Example images of Rad51 negative (GFP 
KD + DMSO 0h post IR) and Rad51 positive (GFP KD + DMSO 8h post IR) cell nuclei. Note that RAD51 foci were 
morphologically smaller and fainter than γH2AX foci. C. Graph representing relative percentages of RAD51 positive cells 
across different IR timepoints in cell samples with varying ATM status and HDACi treatment. †= vorinostat treatment 
statistically significant compared to untreated cells of same timepoint (P=<0.01), ‡ = ATM deficient cells statistically 
significant relative to WT cells of same treatment and timepoint (P<0.01). Error bars represent the standard deviation of the 
mean. 
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4.0 Discussion 
4.1 Hi-Res Melting as a mutation detection strategy 
 The study employed a novel method for detecting DNA sequence alterations, called Hi-Res 
Melting (see section 2.4). The method was advantageous to this study because it allowed 
rapid, high-throughput analysis of patient samples. Considerably more patient samples could 
be assessed for mutations in the time available in comparison to if each sample had been 
sequenced via the Sanger method. However, one downside of the method is that it only infers 
the possible presence of DNA sequence changes. The confirmation of any mutations present, 
and access to information concerning the nature and characteristics of any sequence changes, 
still requires the “flagged” samples to then be sequenced using traditional methods. Another 
potential downside is that there is a very small yet ever-present possibility that certain mutant 
samples may be erroneously classified as WT – some mutations may not cause changes in the 
DNA melting profile that are clear enough for the sample to be flagged as a potential variant. 
The identification of these variants is also very subjective and depends on the individual 
analysing the melting curve data, another potential error source. To be completely confident 
that all mutants had been detected in a cohort, all samples would still have to be sequenced 
via traditional methods. However, Hi-Res Melting is a highly cost-effective and time saving 
method for occasions where this is not feasible, such as if a cohort contains a very large 
number of samples. 
In the context of this study, Hi-Res melting enabled the detection of the homozygous 
c.8786+8 A>C SNP in the PICCLE IM patient sample. Because this mutation was not 
reported to cause any splicing defects (Gumy-Pause et al., 2006; Meier et al., 2006),  it was 
unlikely to have been detected through western blot analysis of the ATM protein product, or 
analysis of ATM mRNA via reverse transcriptase PCR (RT-PCR). There were, however, 
 56 
 
many false positives that appeared to have variant melting curves, but upon sequencing were 
revealed to be WT (fig. 8). This may have been caused by the presence of non-specific 
product generated by unclean PCR reactions, or due to the cohort being fairly small (28 
samples). Due to the method relying on comparisons between individual samples to detect 
and isolate variants, false positives are less likely the larger the sample size, because 
negligible differences in WT melting curves would be less prominent.  
Overall, Hi-Res Melting proved to be a useful tool in analysing ATM exon sequences quickly, 
but problems with PCR reaction optimisation were also encountered (see section 3.1). Due to 
time constraints, it was not possible to continue the optimisation process and complete the 
analysis of the cohort, and the overall aim of identifying any loss of function ATM mutants 
that could then be used in primary tumour cell cytotoxicity assays was not achieved. It was 
therefore decided that experiments to assess the synergic potential of PARPis and HDACis in 
ATM-deficient B-CLL would be carried out on isogenic B-CLL tumour cell lines treated with 
ATM shRNA to induce ATM knockdown, rather than ATM-null primary tumour samples. 
4.2 PARP inhibition did not have a significant cytotoxic effect on CII and MEC-1 cells 
regardless of ATM status 
 Firstly, no significant difference in sensitivity to the PARP inhibitor olaparib was observed in 
cells of differing ATM status. This was in contrast with previous studies, and it was expected 
that ATM deficient tumour cells would show an increased sensitivity to PARP inhibition 
(Weston et al., 2010). In the CII cell line, olaparib treatment in both WT and ATM cells rarely 
produced a statistically significant cytotoxic effect at any dose, although a general trend of 10 
µM olaparib having a slight killing effect was observed. However, at this high dose, off-target 
effects are not unlikely. 
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 A possible explanation for this perceived resistance to olaparib was that the ATM 
knockdown of CII cells was shown to be incomplete; residual levels of ATM protein were 
detected via western blot staining (fig. 9B). Rad51 foci analysis also suggested that HR was 
still active in ATM shRNA treated CII cells (fig. 13C), also providing a possible explanation. 
However, MEC-1 cells displayed highly efficient ATM knockdown, with no ATM protein 
band visible (fig. 9B), and MEC-1 cells responded to olaparib even more unexpectedly than 
CII cells. In MEC-1 cells, olaparib had no cytotoxic effect at any concentration tested, and 
even produced a marginally positive effect on cell proliferation at higher concentrations. The 
fact that MEC-1 cells were p53 mutant could counter-intuitively contribute to this - there has 
been evidence of PARP1 inhibition causing medullablastomas in p53 
-
/
-
 mice, implicating a 
tumour suppressive role for PARP1 in that particular cancer (Tong et al., 2003), thus it is not 
out of the question that this could happen in p53 mutant B-CLL. Indeed, disruption of DNA 
repair mechanisms leads to increased genomic instability, which is a leading cause of cancer 
in the first instance (Shaheen et al., 2011), and thus may lead to further oncogenic mutations 
and increased aggressiveness if  DNA damage levels are not sufficient to lead to mitotic 
catastrophe. However, this is highly unlikely and has not been reported in progressive B-CLL.  
If cell viability loss was indeed through the accumulation of unrepaired DNA damage,  p53 
loss would have been expected to increase the cytotoxic effect of olaparib rather than oppose 
it due to further loss of cell cycle arrest mediators, especially because ATM and p53 have 
convergent roles (Stankovic et al., 2002b). Thus, more studies are required to clarify the 
underlying mechanisms of this apparent resistance to olaparib in p53 mutant cells. 
4.3 ATM wild-type cells exhibited increased sensitivity to HDAC inhibitors 
 Both CII and MEC-1 cell lines were sensitive to the higher concentrations of HDAC 
inhibitors used. Unexpectedly however, in both cell lines, ATM wild type cells appeared to be 
more sensitive to HDACis than ATM knockdown cells. This effect was very unlikely to have 
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been caused by the GFP shRNA negative control, because preliminary dose response 
optimisation experiments in untreated CII and MEC-1 cells showed almost identical patterns. 
There is evidence to suggest that HDAC inhibition can lead to p53 mediated apoptosis 
through DNA damage caused by reactive oxygen species (ROS) (Petruccelli et al., 2011; 
Wang et al., 2012) or p53 hyperacetylation (Oh et al., 2012). Thus, the ATM/p53 pathway 
may be responsible for HDAC induced killing through apoptotic mechanisms, and HDACis 
may induce more cell killing in WT cells with intact ATM/p53 pathways through apoptosis 
than in ATM deficient cells though the proposed theory of unrepaired DNA damage 
accumulation or autophagy - hence why WT CII cells displayed more sensitivity to HDAC 
inhibitors than ATM knockdown cells. This cannot explain the same phenomenon in the p53-
mutant MEC-1 cells, however, which were also more sensitive overall to lower doses of 
HDACis to the point at which lower doses had to be used. Perhaps the loss of p53 function 
resulted in an even further loss of cell cycle regulation and DNA repair, thus more capacity to 
accumulate lethal levels of unrepaired DSBs. Since p53 and ATM have convergent roles 
(Stankovic et al., 2002b), this may also explain why MEC-1 ATM mutant cells were not 
preferentially sensitive to HDACis – the p53/ATM pathway was already impaired - although 
if this was the case, it would have been expected that MEC-1 cells would respond to olaparib 
treatment. 
In CII cells, as the concentration of HDACi increased, the surviving fraction fell as was 
expected – HDAC inhibitors have been shown to decrease proliferation, and induce apoptosis 
and/or differentiation, as well as mediate the DNA damage response. Contrastingly, MEC-1 
cells often showed dramatic increases in viable cell levels relative to the untreated controls, 
before sharply dropping off at marginally higher HDAC doses. This effect occurred regardless 
of ATM status, and was consistently observed throughout the experiments. The reasons as to 
why this occurred are unknown. One speculation might be that sublethal levels of HDAC 
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inhibitor promotes euchromatin which is conducible to gene transcription and more accessible 
to transcription factors (Federico and Bagella, 2011), therefore possibly leading to 
upregulation of oncogenic cell proliferation genes in MEC-1 cells. 
4.4 PARPi and HDACis did not selectively synergise in ATM knockdown CII cells 
Based on recent findings (Weston et al., 2010), It was hypothesised that the PARP inhibitor 
olaparib would induce sensitivity to HDAC inhibitors in ATM mutant cells, through the 
accumulation of unrepaired SSBs that are converted to DSBs upon DNA replication, resulting 
in cell death through the accumulation of critical levels of unrepaired DSBs. However, it was 
not conclusively observed that ATM deficient cells were selectively sensitive to PARP and 
HDAC inhibition. Although WT cells were more sensitive to HDACi, both WT and ATM 
knockdown CII cells exhibited some PARPi and HDACi synergy at certain doses. PARPi and 
HDACi have been shown to induce apoptosis through DNA damage, and synergise 
accordingly in colon cancer cell lines (Adimoolam et al., 2007). ATM deficient cells are 
likely to have defective apoptotic responses to DNA damage due to an impaired p53/ATM 
pathway, a key reason as to why ATM or p53 null B-CLL is resistant to common therapies 
(Stankovic et al., 2004; Weston et al., 2010). It is therefore possible that PARPi and HDACi 
were indeed causing unrepaired DNA damage in both cell lines, but WT cells were being lost 
through apoptosis while the ATM-deficient cells were lost through other mechanisms such as 
mitotic catastrophe or autophagy-induced cell death, but to a lesser extent. More detailed 
studies into the mechanisms by which cell viability was being lost are required to either 
confirm or reject this speculation. However, the continued presence of Rad51 positive cells, 
as revealed by immunofluorescence, suggested against HR being fully compromised and 
indicated that DSB repair was still occurring, as is next explained. 
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4.5 Homologous recombination was still active in ATM KD CII cells 
The addition of 3 µM vorinostat to WT cells lowered the amount of Rad51 positive cells 
across 24 hours, with a particularly prominent effect up to 1 hour after DSB occurrence. This 
is consistent with HDACs being required for HR (Robert et al., 2011). HDACs 9 and 10 are 
particularly important in HR (Kotian et al., 2011), which are targets of the pan-HDAC 
inhibitor vorinostat used in the experiment.  The effects of vorinostat on ATM WT cells was 
very similar to the characteristics of untreated ATM KD cells, but was even more prominent. 
HDACs may be directly involved in HR (Robert et al., 2011) as previously discussed in 
section 1.9, explaining why HDAC inhibition resulted in a net reduction of Rad51-positive 
cells seen at early timepoints in WT cells. Vorinostat treated ATM deficient cells also showed 
a further loss of Rad51 positive cells across all timepoints relative to ATM deficient untreated 
cells. However, there was still a relatively high level of Rad51 positive cells even in ATM 
shRNA and HDACi treated samples, meaning that HR was impaired but still functional. This 
may explain why ATM deficient cells were less susceptible to HDAC inhibition – HR was 
still active and the cells were therefore not vulnerable to the inhibition of parallel DNA repair 
pathways. 
4.6 Experimental shortfalls 
 There were a number of shortcomings to the cytotoxicity experiments. The main limitation to 
the study was that B-CLL cell lines were used rather than primary B-CLL tumour samples, 
and that stable ATM knockdowns were used rather than ATM mutants. The unavailability of 
ATM mutant primary tumour samples was unfortunate, as they constitute the best models for 
B-CLL cytotoxicity experiments in vitro and have been used in preceding studies (Weston et 
al., 2010). The experimental approach may have been compromised for a number of reasons: 
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a). Cell lines are known to acclimatise to specific cell culture conditions over time and behave 
differently to primary cells, thus, cell lines are not always an authentic representation of how 
primary tumours would be affected by cytotoxic drugs. 
b). More specifically, the genes involved in the DDR are complex, involve much cross-talk 
and are often convergent and pleiotropic (Shaheen et al., 2011). Stably transfected ATM 
knockdown cells may have undergone the upregulation of redundant parallel pathways other 
than PARP and HDAC mediated mechanisms to compensate for the loss of ATM. The 
occurrence of this phenomenon becomes increasingly likely with time, as the cells undergo 
increasing rounds of replication and are passaged multiple times. This could have occurred in 
both CII and MEC-1 cells, explaining a lack of response to PARP and HDAC inhibition in 
ATM knockdown cells. 
c). In CII cells, the ATM knockdown was incomplete and the residual ATM protein still 
present may have been enough for ATM-mediated HR. Indeed, knockdowns are not always 
the best approach for studying gene loss – it is not possible to achieve total knockout of the 
gene, and ATM
-/-
 knockout cells may have been more suitable.  
If cell lines are to be used again, the knockdown must be efficient. Inducible ATM 
knockdown systems might also be a better approach, because this would allow the 
comparison of the presence and absence of ATM in the same cells, maintaining exactly the 
same culture conditions. It would also restrict the potential ability of the cells to adapt to the 
loss of ATM and restore HR mechanisms through other mediators. 
Another problem may lie with the fact that poly(ADP-ribosyl)ation and acetylation are such 
ubiquitous processes throughout cells (Smith and Workman, 2009).  Thus, off-target effects 
independent of the DDR could not be discounted. For PARP activity, this was addressed by 
using only up to 10 µM olaparib because concentrations higher than 10 µM are significantly 
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more likely to induce off-target effects (Weston et al., 2010). In this instance however, higher 
doses may have been suitable to use due to the lack of response to PARP inhibition, even if 
only to confirm that PARP inhibition could indeed cause a significant cytotoxic effect in the 
cell lines or not. As far as HDACis are concerned, around 85% of proteins are acetylated (Su 
et al., 2008), thus higher doses of HDAC inhibitor may have caused off-target effects that 
contributed to the cytotoxicity. From a clinical perspective, off-target effects are undesirable 
and lower drug tolerances. Detailed analysis of acetylome changes would be required to 
establish if off-target effects caused by HDAC inhibition were impacting on cell viability, as 
well as in vivo experiments to assess any potential side effects. 
The cell viability assay that was used was also limiting in that it lysed the cells and only 
quantified the levels of ATP present as a measure of viable cells - no detailed information 
could be obtained as to the mechanisms of cytotoxicity, such as any cell cycle blocks, through 
induction of apoptosis, senescence, mitotic catastrophe or autophagy-related cell death. Thus, 
more detailed studies are required to establish the molecular mechanisms responsible for the 
results that were obtained.  Additionally, the method of ATP quantification is not a 
completely faithful representation of viable cells, as cells will naturally vary in ATP levels, as 
well as between samples due to varying culture conditions. Additional cell viability 
quantification assays should therefore be carried out before any final conclusions are made, 
such as a manual cell counting method.  
The immunofluorescence experiments also had a number of shortfalls. Due to time 
constraints, it was only possible to assess Rad51 mediated HR in one cell type, and more 
repeats of the same experiment would have to be performed to increase the reliability of the 
data obtained. Due to the aberrant responses to the drugs seen in MEC-1 cells, CII cells were 
used, but as aforementioned the ATM knockdown was not complete which may have 
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impacted on the results. Had the time been available, HR in cells of differing treatment and 
ATM status would have been analysed in more detail, along with the impact of p53 loss on 
HR. Firstly, different variations of HDAC inhibitors and dose levels would have enabled a 
broader picture of the effects on HR. Assessing the effects of combined PARPis and HDACis 
on HR would also have provided useful information. It would have also been beneficial to 
visualise the effects of PARP inhibition on NHEJ mediators such as DNA-PKcs, which like 
Rad51 form foci at sites of DNA damage and thus their induction is quantifiable (Lou et al., 
2004).  Assessing the prevalence of Rad51/ γH2AX positive cells for longer times than 24 
hours after IR might also be a viable study, because ATM has been implicated in absolving 
foci and resuming the cell cycle after HR is complete (Battu et al., 2011). Thus, loss of ATM 
could result in cellular senescence if the foci persist. Detailed cell cycle analysis would also 
reveal any cell cycle blocks that might be induced by PARP/HDAC inhibition.  
4.7 Conclusions and future perspectives 
 The data observed in this study does not suggest that ATM deficient B-CLL cells are 
selectively sensitive to combined PARP and HDAC inhibition. Synergy was observed 
between PARP and HDAC inhibitors in B-CLL cell lines, although not significantly more so 
in ATM knockdown cells.  Future work must be undertaken in primary tumour cells of 
differing ATM status for the most reliable results in vitro.  Additionally, in vivo experiments 
are required to further validate the tumour killing effects of PARPi and HDACi combined 
therapies. 
The fact that WT cells were seen to be more susceptible to HDAC inhibitors than ATM 
knockdown cells is not necessarily a negative observation from a clinical point of view, as 
this may indicate that HDAC inhibitors are good potential candidates for treating progressive 
B-CLL forms that are ATM WT. HDACis are generally well tolerated (Federico and Bagella, 
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2011), as are PARPis (Audeh et al., 2010; Vasiliou et al., 2009), which is a highly desirable 
trait for cancer therapeutics, particularly those which are likely to be administered to people of 
vulnerable age groups as in B-CLL. However, the mechanisms of HDACi cytotoxicity in B-
CLL still need to be elucidated, and the observations may have been caused by off-target 
effects that may cause drug toxicity. Work must be done to establish effective dose tolerance 
levels, as well as the elimination of any potential off-target effects.  
The development of both specific and potent treatments for progressive forms of B-CLL 
remains important, both to increase overall survival rates and the quality of life of patients, 
and despite the difficulties encountered during the study, the use of PARP and HDAC 
inhibitors in treating ATM-deficient B-CLL still remains a promising option. To unlock the 
potential of these compounds, more detailed studies are required into the tumour-killing 
effectiveness, the specificity to tumour cells and the specific molecular mechanisms by which 
the killing is achieved. 
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Appendix 
 
 
Exon 
 
 
Original Primer Sequence 
(5' - 3') 
Original 
Optimum  
Tm (
o
C) 
 
New Sequence 
New 
Optimum 
Tm (
o
C) 
4F 
4R 
CACACCTCTTTCTCTCTATATATGC 
ATTTCAAGGAAAAATTGAATTTAAG 
61  
GGAAAAATTGAATTTAAGTAATTTACTAC 
 
5F 
5R 
TGATTAGTAACCCATTATTATTTC 
GGAAGCAAAGATAAATGTTAAGACTTACAC 
61  
AATAAAGACAGTAAAATAAATTTGAATAG 
 
6F 
6R 
ATTGGTCTTGTAGGAGTTAGGCCTTG 
AAAAACTCACGCGACAGTAATCTG 
65   
7F 
7R 
TAAATAGTTGCCATTCCAAGTGTC 
TGGTGAAGTTTCATTTCATGAGG 
65   
8F 
8R 
CCTTTTTCTGTATGGGATTATGGA 
TACTGAGTCTAAAACATGGTCTTGC 
62   
9F 
9R 
TTCTTTCAGCATACCACTTCATAAC 
TGAATGAAGAAGCAAATTCAAAACAG 
60   
10F 
10R 
TGGGAGCTAGCAGTGTAAACAGAG 
CAGGAAATTTCTAAATGTGACATGAC 
65   
11F 
11R 
GCTCAAAAAAAAAAAAAAGAAAAAAGTGG 
AAATGACTTAGTTCTGGTTGAGATG 
65   
12F 
12R 
TCCTTTTAGTTTGTTAATGTGATGG 
ACTATGAAAATGATCAGGGATATG 
61   
13F 
13R 
CCTCCAATAGCTTGCTTTTCAC 
AAACAGCAGCATGCTAATGAAC 
64 CGAGCTATTTTTTTAATCAAGAATCTTCC 
CAATCAGGCATAAAGACACAGATAAC 
 
14F 
14R 
GTATTCTTTACATGGCTTTTGGTC 
TACTACCCAGCTAAAATTATCATC 
62   
15F 
15R 
CATATAAGGCCAAAGCATTAGGT 
CCTATTTCTCCTTCCTAACAGT 
61   
16F 
16R 
GAATTTGTTCTTACAAAAGATAGAG 
GAATACATTTCATTCAAATTTATCCGA 
60   
17F 
17R 
GTATGTCCAAGATCAAAGTACACTG 
GGGTGACAGAGAAAGATCCTATC 
64 CTCTTGGTAGTACTCTGTCACTGGTATG 
GGATATTACCTTTATGTACCATTCAACT 
 
18F 
18R 
GTTTTTATTTCTTTGTTGCTTGGTTCT 
CAAAATATGATAGCAAAACAGGAAGC 
65 CTCTAAGAAAAGATGTGTTTTTGAAGCAG 
AGAGCTATATGTTGTGAGATGCATCC 
60 
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Exon 
 
 
Original Primer Sequence 
(5' - 3') 
Original 
Optimum  
Tm (
o
C) 
 
New Sequence 
New 
Optimum 
Tm (
o
C) 
19F 
19R 
CTCCCAAATTGCTGAGATTACAGATG 
ATGAGGCCTCTTATACTGCCAAATC 
65   
20F 
20R 
ATATATGGCTGTTGTGCCCTTCTC 
CATCAGATAAAATCCAAGAGCTTC 
60 ATTATTTCTTGACAACAGAATCTTGG 
AAATTTGCTCACAGCACGTTAAAAGTG 
62 
21F 
21R 
AAACCTGATTTTTTTCCCTCCTAC 
TTTATAAGCTTAACAGAACAGAACACATCAGT 
60   
22F 
22R 
AATAACTGATGTGTTCTGTTAAGC 
AAACTTGCATTCGTATCCACAGAT 
60  
GGAAGATCAGAAGAAATCACTGATG 
60 
23F 
23R 
GTAACTTATAATAACCTTTCAGTGAG 
ACTCATTAACAAACAAAGACTGCT 
60 AGCACAGAAAGACATATTGGAAG 
GTAACTTATAATAACCTTTCAGTGAG 
60 
24F 
24R 
CTATTTCATATTTAACCACAGTTC 
TATGTAAGACATTCTACTGCCATC 
60   
25F 
25R 
TTGTTTGTTTGTTTGCTTGCTTGTTT 
CATATGATAACAGCAAATACATGTTAC 
60 GTTCTGGAATATGCTTTGGAAG 
GTCCAATGTTCCCTTAATTAGC 
60 
26F 
26R 
GTCAAAAAATCTGGAGTTCAGTTG 
GGAAGCTTCTAATAAAATACTCATC 
65  
ATACTATTTCCAAAAGCCTGGTCAGTC 
 
27F 
27R 
GAATGTTGTTTCTAGGTCCTACTC 
GTGAGGGGACTTGCTAAGTATTG 
62   
28F 
28R 
CTTGGAAAAGTTATATATAACCTG 
AACTTAAAGGTTATATCTCATATC 
60   
29F 
29R 
TTTGAGCTGTCTTGACGTTCACAG 
TTGAAATAGACATTGAAGGTGTCAAC 
61   
30F 
30R 
TTTTCATTTTGGAAGTTCACTGGTC 
GGAATGTTCTATTATTAAACTCATC 
61   
31F 
31R 
GTGTATTTATTGTAGCCGAGTATC 
GGAAGAACAGGATAGAAAGACTGC 
65   
32F 
32R 
GACTTCTGAATGAATTTATTTCAGAG 
CACTCAAATCCTCTAACAATAC 
60  
AAAATCACCAATTATACCAAA 
 
33F 
33R 
TTACAGTAAGTTTTGTTGGCTTAC 
CAGATTTTTGAAAAGTACTACTATG 
61   
34F 
34R 
CCAATACGTGTTAAAAGCAAGTTAC 
AACAGGTAGAAATAGCCCATGTC 
60 GATTAGTAGTAATAGAGACATGAGTCAG 
CTGAACTAAATGATGAGAGTCTGAAC 
61 
35F 
35R 
AAACAAAAGTGTTGTCTTCATGCT 
TCCTATATGTGATCCGCAGTTGAC 
64 CTCTGTTGTCACATATTGCTAATCAC 
ACTACACACCTAGGCTACAAACCTG 
62 
36F 
36R 
GTTTTATGTATGATCTCTTACCTATG 
GAAGTATCATTCTCCATGAATGTC 
60   
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Exon 
 
 
Original Primer Sequence 
(5' - 3') 
Original 
Optimum  
Tm (
o
C) 
 
New Sequence 
New 
Optimum 
Tm (
o
C) 
37F 
37R 
CAGTGGAGGTTAACATTCATCAAG 
ACAGTCATGACCCACAGCAAACAG 
65   
38F 
38R 
AAGGTACAATGATTTCCACTTCTC 
CAGCACTCTTTAGATAAACAGGTC 
65   
39F 
39R 
AGCAGTATGTTGAGTTTATGGCAG 
GGATTCCATCTTAAATCCATCTTTC 
65   
40F 
40R 
CCTTATAGCATAGTGGGAGACAG 
CAAGTTACACTCTAGATCCTAAACG 
65   
41F 
41R 
TAAGCAGTCACTACCATTGTATTC 
TACCCTTATTGAGACAATGCCAAC 
65   
42F 
42R 
CAGGAGCTTCCAAATAGTATGTTC 
CACATGGCATCTGTACAGTGTCT 
65   
43+44F 
43+44R 
TAGAGTTGGGAGTTACATATTGGT 
GCACTACACTAGTGATGGCTTTAC 
63   
45F 
45R 
GGTTTCTGTTGATATCTTTGATTAC 
GAGAGGCAAAAAAAAAAAAATCAAGTC 
62   
46F 
46R 
GTCCTTTGGTGAAGCTATTTATAC 
CTCAAGTTTTCAGAAAAGAAGCCA 
65   
47F 
47R 
CCTCTTCTTTATTTTCAGAGTGTC 
GTCACTATTGGTAACAGAAAAGC 
61   
48F 
48R 
CATTTCTCTTGCTTACATGAACTC 
TAGAGATCTCTATCTCTTAATGAC 
62   
49F 
49R 
CATGGTAGTAGTATCAGTAGTAAAAG 
CAGTAAAACACTAATCCAGCCAAT 
62 GAGATGTCATGCAGACAGAGAGGTCC 
GAATCGACCACATGATGGACTGATAG 
 
50F 
50R 
AGTTGGGTACAGTCATGGTAATGC 
CTAAGTAACTATCTTAAGGGTTGCTC 
63   
51F 
51R 
GTGTATTACCTAATTTGAGTGATTC 
AAGACCAAGTCACTCTTTCTATGC 
63   
52F 
52R 
ATCATGTGTGATTTTGTAGTTCTG 
TTCAAGCACAGGGTAGAATATTGG 
65   
53F 
53R 
TTGTGCTAATAGAGGAGCACTGTC 
GTATTTCCATTTCTTAGAGGGAATG 
63   
54F 
54R 
TCTACCCACTGCAGTATCTAGAC 
CAGCCTTGAACCGATTTTAGATG 
65   
55F 
55R 
TGTTGGGTAGTTCCTTATGTAATG 
GGATTACGTTTGTGATTTTAAGCAG 
64 GAAAGGCACCTAAGTCATTGACGAG 
CTCTGTAATAAGTATGTATGCCAGAAG 
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Exon 
 
 
Original Primer Sequence 
(5' - 3') 
Original 
Optimum  
Tm (
o
C) 
 
New Sequence 
New 
Optimum 
Tm (
o
C) 
56F 
56R 
ACTATTCCTGCTTGACCTTCAATG 
GCCAATATTTAACCAATTTTGACC 
61 CTTTGACTCTGAGCTGCATAGT 
 
 
57F 
57R 
TAAGTGCAAATAGTGTATCTGACC 
CATCACTAAAACTCTAAGGGCTAAG 
65 GCCTAAAGTTGTAGTTCTTAACCAC 
GCATTTCTACTCTACAAATCTTCCTC 
 
58F 
58R 
TTGCTATTCTCAGATGACTCTGTG 
GCCTCCCAAAGCATTATGAATATG 
61   
59F 
59R 
CATCAAATGCTCTTTAATGGCCTT 
CTATAATATCTGACAGCTGTCAGCT 
63 GAGCTTTGTCTTCTATGGACAGAG 
CATTTCTTATCTGACAAGGGTTGAC 
 
60F 
60R 
CATCTTTATTGCCCCTATATCTGTC 
TGCCAAACAACAAAGTGCTCAATC 
62   
61F 
61R 
AAGAGATGGAATCAGTGATTTCAG 
AGGCAAACAACATTCCATGATGAC 
62   
62F 
62R 
TTAGCTGTCAAACCTCCTAACTTC 
TTGAGTAGCTGGGATTACAGGTG 
64   
63F 
63R 
AGATATGTTGACAACATGGTGTG 
GAGATACACAGTCTACCTGGTAAG 
65 GTCTAATGAAAGCCCACTCTGCCA 
TGTGTGAAAAGGCTAAGTGCACAA 
62 
64F 
64R 
GATACTGGTTCTACTGTTTCTAAG 
AAAGGTTTCAGTGAGGTGAACAG 
64   
65F 
65R 
GGTGAGCAGTATTTTAAGAAGGTC 
TCCCTACTTAAAGTATGTTGGCAG 
64   
 
 
 
 
 
 
 
 
Table S1 - All ATM primers used in the study, with re-optimised temperatures included. 
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Characteristic CII MEC-1 
Ig Production IgM, λ NT 
IGH genes IGHV1-69UM/IGHD3-
10/IGHJ6 
IGHV4-59M/IGHD2-21/IGHJ4 
IGK/IGL genes IGLV1-4 NT 
FISH data Trisomy/tetrasomy 12 + 
tetrasomy 11q/13q/17p 
NT 
CD38 (% pos. cells) 69 40 
CD38 (MFI fold-increase) 12.1 6.8 
ZAP70 (% pos. cells) 83 2 
ZAP70 (MFI fold-increase) 5, 8 1.1 
TCL1 (%pos cells/MFI) 74%/3.6 71%/4.8 
TCL1 (Western Blot/RT-PCR) + (+) 
TP53 Status Wild Type Mutant 
 
shRNA 
Target 
Sequence 
ATM-1 
(7218) 
 
5'-GATCCCCCTGGTTAGCAGAAACGTGCTTCAAGAGAGCACGTTTCTGCTAACCAGTTTTTA-3' 
          3'-GGGGACCAATCGTCTTTGCACGAAGTTCTCTCGTGCAAAGACGATTGGTCAAAAATTCGA-5' 
ATM-II 
(P480) 
 
5'-GATCCCCGATACCAGATCCTTGGAGATTCAAGAGATCTCCAAGGATCTGGTATCTTTTTA-3' 
          3'-GGGCTATGGTCTAGGAACCTCTAAGTTCTCTAGAGGTTCCTAGACCATAGAAAAATTCGA-5' 
 
GFP 
shRNA 
Control 
 
5'-GATCCCCCGTACGCGGAATACTTCGATTCAAGAGATCGAAGTATTCCGCGTACGTTTTTA-3' 
          3'-GGGGCATGCGCCTTATGAAGCTAAGTTCTCTAGCTTCATAAGGCGCATGCAAAAATCGA-5' 
 
University of Birmingham 
Table S2 - Characteristics of CII and MEC-1 isogenic B-CLL cell lines. NT = not tested. CD38 and ZAP70 % positive 
cells were calculated according to a 30% cut-off. Fold increase of MFI was calculated and considered positive at the 
following limits: >2.5 fold for ZAP70 and >3.5 fold for TCL1. 
 
Table S3 - shRNA oligonucleotides used for stable ATM and GFP negative control knockdowns. Two ATM shRNA 
oligonucleotides were transfected simultaneously to increase the efficiency of the knockdown. Note that the knockdown 
experiments were performed prior to this study and the sequences are included for completeness. 
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Abstract 
The simultaneous imaging of multiple biomarkers within tissues is of high value to both 
experimental and diagnostic histopathology, because it allows for analysis of the spatial and 
temporal relationships of specific molecules, cell populations and tissue components.  
Immunofluorescence (IF) is a highly applicable technique for sample multilabelling, but 
intrinsic pitfalls such as low fluorophore brightness and photostability, tissue 
autofluorescence and spectral bleedthrough can limit the viability of IF in a histopathological 
context. This study has optimised a multiple marker imaging method using indirect IF and 
confocal laser scanning microscopy (CLSM) to simultaneously image three separate B-
lymphocyte markers of CD19, κ- and λ- immunoglobulin light chain antigens alongside a 
nuclear counterstain in reactive lymph node cryosections. Building on preliminary 
experiments which used older generation fluorophores, a staining and imaging protocol 
utilising the more photostable Alexa fluorophores was optimised. Secondary antibody 
dilutions of Alexa 488, 568 and 647 which produced maximum signal and minimum 
nonspecific fluorophore binding were determined. In addition, microscope imaging settings 
were established that minimised tissue autofluorescence, spectral bleedthrough and an optimal 
signal/noise ratio. This imaging method could be applied in a clinical context for 
immunophenotyping and identifying B-lymphocyte populations with abnormally skewed κ/λ 
ratios within lymph nodes, an indicator of monoclonality and potential neoplasia. Future 
studies will continually develop this imaging method for different immunological antigens for 
potential use in diagnostic and prognostic histopathology of lymphomas and lymphatic 
leukaemias, and for research towards cancer therapies targeting the specific molecular 
mechanisms of tumourigenesis. 
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List of Abbreviations 
CLSM  Confocal laser-scanning microscopy 
DAPI            4',6-diamidino-2-phenylindole 
FFPE  Formalin-fixed paraffin embedded 
FITC  Fluorescein isothiocyanate 
IF  Immunofluorescence 
Ig  Immunoglobulin 
IHC  Immunohistochemistry 
PBS  Phosphate buffered saline 
PMT  Photomultiplier tube 
TRITC  Tetramethyl rhodamine iso-thiocyanate  
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1.0 Introduction 
1.1 The importance of monitoring specific markers in histology  
Histology is defined as the study of tissues, and is an essential tool in many areas of 
biomedical research and medicine. In medicine, histology is often used for the acquisition of 
diagnostic and prognostic information through the study of diseased tissues, a field defined as 
histopathology. Traditional histological methodology commonly involves light or electron 
microscopy in combination with biological staining methods to resolve morphological and 
cytological details (Mahon, 2011). However, as more progress is made on elucidating the 
molecular mechanisms of disease, it is often necessary to visualise and/or quantify the 
expression of specific proteins within tissues (Mahon, 2011). Using cancer as an example, 
patients diagnosed with the same form of cancer and the same histopathologically defined 
disease stage often have largely differing prognoses due to differing underlying molecular 
mechanisms of the disease. Some examples of surface markers implicated as indicators of 
poor disease prognosis include the presence of CD44 in colorectal cancer (Belov et al., 2011), 
CD38 and CD49d in chronic lymphocytic leukaemia (CLL) (Del Poeta et al., 2001) or HER2 
in breast cancer (Qui Wen-sheng et al., 2009). The treatment of certain molecularly defined 
cancer forms must often take alternative approaches, such as early surgery or more aggressive 
courses of chemotherapy and radiotherapy, to ensure the best possible chance of remission 
and patient survival (Li et al., 2010).  
As the understanding of the molecular mechanisms of cancer increases, the identification of 
such markers may also open up new more effective and less toxic personalised treatment 
options that specifically target the marker molecule itself, or downstream effectors of the 
signalling pathways it mediates (Sawyers, 2004). Thus, the monitoring of specific markers is 
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important for both biomedical research to develop such drugs, and from a clinical 
histopathology context to identify forms of disease eligible for such treatment. 
 The most common histological methods to identify specific molecules involve 
immunophenotyping via immunohistochemistry (IHC).  IHC is defined as the process of 
detecting antigens in tissues via the use of antibodies specific to the antigen of interest (Key, 
2009; Renshaw, 2005). The two most widely used IHC methods are enzyme-based IHC and 
immunofluorescence (IF) (Renshaw, 2005). 
1.2 Commonly used histological methods for 
analysing expression of specific markers  
 Enzyme/substrate based IHC is the most 
common method used in both research and 
diagnostic histopathology, the basis of which is 
to produce staining localised to areas of tissue 
expressing a specific antigen via the catalysis 
of a reaction involving a subsequently added 
colourless chromogenic substrate, which 
produces a dye compound (Key, 2009; 
Renshaw, 2005). As an example, avidin/biotin 
methods are the most common approaches (fig. 1) 
(Key, 2009). IHC stained tissue sections are analysed 
under a brightfield microscope, and the level and 
localisation of the chromogenic compound gives information as to the level of expression as 
well as the spatial localisation of the antigen of interest (Key, 2009; Robertson et al., 2008).  
Figure 1 - Diagrammatic representation of indirect 
avidin/biotin immunohistochemistry. Avidin has a 
high affinity for biotin, thus the avidin/enzyme 
complex binds to the secondary bitinylated 
antibody and catalyses the reaction of the substrate 
into a chromogenic compound. The image below 
depicts streptavidin/horseradish peroxidase IHC 
labelling against C4d antigen in renal peritubular 
capillaries (brown = positive) (Troxell et al., 2006). 
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Alternatively, IF is based on the physical phenomenon of fluorescence, whereby a given 
molecule may absorb a photon of a specific wavelength, causing an electron to jump to a 
discrete singlet higher energy state (Semwogerere and Weeks, 2005).  Provided no molecules 
around it can absorb the energy through collisions to return it to ground state, the excited 
molecule may spontaneously emit a photon of longer wavelength and thus lower energy than 
that of the exciting photon (Semwogerere and Weeks, 2005) (Fig. 2A,B). 
Immunofluorescence takes advantage of this phenomenon via the conjugation of fluorophores 
to antibodies (fig. 2A depicts the indirect immunofluorescence mechanism). Light of a 
specific wavelength is used to excite fluorophores that are conjugated to antibodies, and the 
emitted photons are collected and observed by eye through an eyepiece (if the emission 
wavelength is visible) or detected electronically and a digital image formed (Semwogerere 
and Weeks, 2005). The applications of fluorescence microscopy in molecular biology are 
widespread, but this study is primarily concerned with the applications of 
immunofluorescence in histology.  
Figure 2 - A. Diagrammatic representation of indirect immunofluorescence. Image below = renal peritubular 
capillaries stained against C4d antigen. Green = positive. (Troxell et al., 2006). B. Diagram illustrating physical 
mechanism of fluorescence. A high energy photon raises the fluorophore to an excited energy state. Some energy 
is lost to surrounding molecules before the rest of the energy is lost as an emitted lower energy photon, and the 
fluorophore returns to ground state (Semwogerere and Weeks, 2005). 
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1.3 Enzyme IHC vs. IF for multiple marker imaging 
Enzyme based IHC is the most popular method for visualising specific markers in histology 
because the protocol is simple to perform, and little specialised equipment is required (Arzt et 
al., 2009). However, image resolution is limited by the optical restrictions of light microscopy 
as well as the precipitation of the chromogenic substrate (Robertson et al., 2008). 
Chromogenic compounds are also prone to signal saturation, which prevents semi-
quantitative analysis of the level of expression of such markers (Robertson et al., 2008). Most 
importantly, imaging multiple markers on the same tissue section is difficult and impractical 
with enzyme IHC, because any detection systems must be highly sensitive and the 
chromogenic compounds used must contrast highly to accurately define individually stained 
areas (Robertson et al., 2008). Double and sometimes even triple antigen staining is still 
possible using highly contrasting chromogenic compounds, but the requirement of highly 
visually contrasting compounds often requires the use of a diffuse and less specific 
chromogen (Vanderloos, 2008). If instead similar colours are used, the analysis of such stains 
may require novel imaging techniques to separate two visual similar compounds, such as 
spectral unmixing (Vanderloos, 2008). Generally, the protocols become increasingly more 
specialised and difficult to perform as more antigens are probed (Krenacs et al., 1990; 
Robertson et al., 2008; Vanderloos et al., 1988; Vanderloos et al., 1989). 
Due to the availability of fluorophores with distinct spectral profiles, it is relatively simple to 
resolve more than two markers simultaneously using IF in better resolution. This is a highly 
beneficial and desirable trait for both biomedical research and diagnostic histopathology, as it 
allows for the visualisation of spatial and temporal relationships between antigens (Brelje et 
al., 2002; Demandolx and Davoust, 1997; Ma et al., 2007; Robertson et al., 2008).Therefore, 
for imaging multiple markers in high resolution simultaneously, IF is a more suitable option 
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than enzyme based IHC. However, although this is the case, IF also has its downsides and 
pitfalls that must be overcome. 
1.4 IF imaging pitfalls 
The concept of immunofluorescence staining against multiple markers for histological 
purposes has been around for a relatively long time (Coons et al., 1942; Ferri et al., 1997; 
Kupper and Storz, 1986; Robertson et al., 2008). However, although IF is precise and high 
resolution, there are several fundamental obstacles that can reduce the effectiveness of IF for 
use in research and diagnostic histopathology. 
 Firstly, constant exposure to excitation wavelengths causes fluorophores to permanently lose 
brightness, a process termed photobleaching. This is a problem for clinical histological 
applications, as tissue sections may often require imaging on multiple occasions. Secondly, 
long-term storage of IF stained material also results in fluorophore degradation (Eggeling et 
al., 1998), and feasibility of long-term storage is an important prerequisite for diagnostic 
pathology for documentation purposes and verification of diagnoses (Ermert et al., 2001). The 
quality of fluorophores widely available around the time of initial studies, such as fluorescein 
isothiocyanate (FITC), tetramethyl rhodamine iso-thiocyanate (TRITC) and cyanine based 
dyes such as Cy5, could not address these problems because they photobleach relatively 
quickly and do not store well (Berlier et al., 2003; Entwistle and Noble, 1992; Ferri et al., 
1997; Panchuk-Voloshina et al., 1999; Robertson et al., 2008). In comparison, IHC stained 
tissue sections can be viewed an almost unlimited amount of times without the chromogenic 
precipitate deteriorating, and can be stored for many years without requiring darkness or 
refrigeration (Key, 2009; Renshaw, 2005). 
Two other major issues with IF that can limit its viability and application are tissue 
autofluorescence and spectral bleedthrough. Some tissue types possess natural fluorophores 
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that fluoresce over a broad range of wavelengths and therefore disrupt the interpretation of IF 
stained tissues, as fluorophore staining may become confused with endogenous tissue 
autofluorescence (Robertson et al., 2008). For example, vascular and connective tissues 
strongly autofluoresce because elastin and collagen possesses natural fluorophores (Rigacci et 
al., 2000).  
Spectral bleedthrough is a large problem for multifluorescence imaging, which refers to 
incidences whereby the emission of one fluorophore is detected through a photomultiplier 
channel or filter set intended for a second fluorophore (Brown, 2007). This occurs because 
some fluorophores, FITC and TRITC for example, have broad emission and absorption 
spectra that largely overlap. Crosstalk between fluorophores can also be an issue if the two 
fluorophore-labelled biomarkers are in close molecular proximity, whereby the emission 
wavelength spectrum of one fluorophore overlaps with the excitation spectrum of a second, 
resulting in subsequent emission of the second fluorophore (Brown, 2007). These imaging 
artefacts can incorrectly alter the interpretation of images due to the presence of false positive 
features in certain detector channels (Brown, 2007). Using epifluorescence microscopy, these 
experimental pitfalls are relatively difficult to avoid unless fluorophores with highly distinct 
emission and absorption wavelength spectra are used, which limits the amount of markers that 
can simultaneously be imaged, further reducing the feasibility of IF labelling (Robertson et 
al., 2008). 
For these reasons, such studies have not been widely accepted by the scientific community 
(Ferri et al., 1997; Robertson et al., 2008). However, more recent studies have opted for new 
generation Alexa fluorophores, which generally have higher quantum yields (the ratio at 
which a photon is emitted for every photon absorbed) and/or extinction coefficients (the 
efficiency of the fluorophore at absorbing light of a given wavelength), and are therefore 
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brighter than older generation dyes (Panchuk-Voloshina et al., 1999, Table S1). In addition, 
Alexa dyes are more photostable compared to more photolabile older dyes of corresponding 
spectral profiles (Benchaib et al., 1996), meaning that low-abundance biological structures 
within tissues can be imaged with great sensitivity and selectivity, and tissue samples can be 
imaged and re-imaged for extended time periods (Panchuk-Voloshina et al., 1999; Robertson 
et al., 2008). Fluorescein and rhodamine based dyes, such as FITC and TRITC respectively, 
as well as sulfonated indocyanine dyes such as Cy5 also have a tendency to quench 
(reversibly lose fluorescence brightness) upon conjugation to other molecules such as 
proteins, due to dye molecule interactions, aggregation and formation of non-fluorescent 
derivatives (Berlier et al., 2003; Panchuk-Voloshina et al., 1999; Ravdin and Axelrod, 1977; 
Valdesaguilera and Neckers, 1989). This is a problem for indirect IF, as IF utilises 
fluorophore-conjugated immunoglobulin molecules.  Alexa dyes are also insensitive to pH 
between 4 and 10 compared to these older fluorophores (Panchuk-Voloshina et al., 1999). 
In addition to the use of modern dyes, confocal fluorescence laser scanning microscopy 
(CLSM) has been implicated as a better option to traditional epifluorescence approaches. 
Such improvements to IF methodology have increased the viability of IF in both experimental 
and diagnostic histopathology. The principles of CLSM are explained in the following 
section. 
1.5 Principles of CLSM  
CLSM differs to standard fluorescence microscopy in a number of ways. The most prominent 
difference is that a pinhole aperture is incorporated into the optical mechanism, which serves 
to eliminate photons emitted from fluorophores that do not originate from the focal plane 
(Paddock, 2000; Semwogerere and Weeks, 2005) (fig. 3).This allows for a visualisation 
method termed optical sectioning, where thin sections along the z axis of thick samples can be 
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imaged non-invasively and in high resolution by eliminating out of focus light (Finkpuches et 
al., 1995; Paddock, 2000; Semwogerere and Weeks, 2005). Widefield fluorescence 
microscopes generally visualise around 2-3 µm thick z sections, while confocal microscopes 
visualise around 0.5 µm sections, the width of which can be adjusted to suit the sample 
(Paddock, 2000; Semwogerere and Weeks, 2005). This feature means that is it also possible 
to resolve separate but stacked features within the z-plane, which otherwise would appear as 
one blurry entity in widefield imaging.  Additionally, due to high axial resolution (Sheppard, 
1989), sharp 3D images of samples can be produced by sequentially scanning different focal 
planes and subsequently stacking the images, a process termed z-stacking (Semwogerere and 
Weeks, 2005).  
Another major difference is the excitation light source. Rather than standard mercury or 
xenon arc lamps, CLSM illuminates samples using high-powered monochromatic lasers 
(Paddock, 2000; Semwogerere and Weeks, 2005). Intense, bundled laser light sources are 
preferentially used because pinhole apertures generate optical sections by blocking out 
defocused light emitted from fluorophores, and therefore cause a loss of signal strength 
reaching the detector (Semwogerere and Weeks, 2005). Thus, conventional lamps do not 
provide light of a high enough intensity for enough emitted photons to be collected for good 
quality imaging. CLSM systems acquire images through the sequential scanning of laser lines 
across a sample, and images are digitally rebuilt from recorded point intensities according to 
x-y coordinates (Semwogerere and Weeks, 2005). Although CLSM systems are usually more 
expensive and require additional training for proficient use, CLSM has many benefits over 
regular fluorescence microscopy which increase the applicability of a multilabelling IF 
method to histopathology. 
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Figure 3 - Schematic diagram of a confocal laser scanning fluorescence microscope. An inverted setup is depicted, similar to 
the primary instrument used for this study. Excitation wavelengths are reflected by the dichroic mirror through the objective 
lens and onto the sample, while returning emitted light wavelengths pass through it. The scanning unit sequentially alters the 
path of the excitation beam to scan across the x and y axis and build an image of the sample. The pinhole restricts light 
reaching the detector to only in-focus light, from which an image is digitally rebuilt. The wavelength values depicted are 
typical values used for imaging fluorescein isothiocyanate (FITC) or Alexa 488 fluorophores. 
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1.6 Advantages of CLSM in histology  
As well as the benefits of being able to obtain high-resolution images of thin optical sections, 
the features of CLSM can reduce some common imaging problems often encountered during 
regular fluorescence microscopy when used in a histological context.  
Many features of CLSM act to reduce autofluorescence and spectral bleedthrough, and thus 
CLSM constitutes a better option for imaging multiple markers via IF. Firstly, thin optical 
sections reduce the volume of tissue that can contribute to autofluorescence (Ma et al., 2006; 
Robertson et al., 2008). Secondly, the monochromatic excitation lasers are of much narrower 
wavelength (<5 nm) in comparison to standard fluorescence mercury vapour lamps (250-800 
nm) (Robertson et al., 2008). This has two benefits, in that much of the spectrum that can 
cause autofluorescence is removed, and also that spectral bleedthrough is less likely to occur 
due to the decreased potential of simultaneously exciting two separate fluorophores with one 
excitation line. More precise, numerically defined emission collection windows are also 
available on confocal systems, further reducing the potential for autofluorescence and spectral 
bleedthrough (Paddock, 2000; Robertson et al., 2008). In addition, CLSM systems have the 
added option of alternately scanning each laser line across the sample, so that only one 
fluorophore species at a time is excited but an image comprised of multiple fluorophores is 
obtained (Brown, 2007; Robertson et al., 2008). This further reduces the chance of spectral 
bleedthrough, because at any given time during collection only one laser line is active and 
only one emission collection window is open (Robertson et al., 2008). Some confocal systems 
can rapidly oscillate laser lines sequentially either electronically or through the use of 
acousto-optic tuneable filters (AOTF), and can therefore achieve this sequential excitation and 
emission collection with only millisecond delays between laser lines  (Brown, 2007). 
 89 
 
These features, combined with the rejection of out of focus blur, also mean that more accurate 
quantitative comparison of multifluorescence signals is possible (Demandolx and Davoust, 
1997; Sandison and Webb, 1994), and CLSM is a highly viable approach for the spatial and 
temporal resolution of specific antigens in histopathology.  
However, the use of new generation fluorophores is of even greater importance than when 
using standard fluorescence microscopy. Increased fluorophore photostability is an essential 
attribute in CLSM for a number of reasons. Firstly, the high intensity laser light source means 
that photobleaching occurs faster (Paddock, 2000). Secondly, although the pinhole blocks 
emitted light originating from the focal plane, the surrounding areas of the tissue along the z-
axis are still exposed to excitation wavelengths and therefore will also photobleach (Brown, 
2007; Paddock, 2000). Thirdly, the production of 3D images of tissues requires repeated 
exposure of the same area to excitation wavelengths (Paddock, 2000; Semwogerere and 
Weeks, 2005). The higher quantum yield of the new fluorophores is also beneficial (Panchuk-
Voloshina et al., 1999), particularly because the pinhole blocks out much of the signal 
reaching the detector to generate optical sections (Semwogerere and Weeks, 2005). One 
further advantage of these next generation fluorophores, especially for clinical histopathology, 
is that they have been shown to store more effectively, and studies have found that tissues 
stained with Alexa secondaries can be stored at -20 
o
C for at least nine months without a 
detectable loss of staining quality (Robertson et al., 2008). 
1.7 Recent advances of imaging multiple markers using confocal microscopy in histology  
Multiple antigens have been successfully imaged via IF and confocal microscopy for a wide 
range of tissues and tissue processing methods. For example, cytokeratin 8/18, vimentin and 
oestrogen receptors have been simultaneously imaged in both malignant and normal breast 
tissue for a comparison of spatial expression and distribution of markers (Robertson et al., 
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2008). Similarly, the prognostic significance of caveolin 2 in breast cancer has been analysed 
via simultaneously imaging caveolin 1, caveolin 2 and p63 (Savage et al., 2008). An 
additional study investigated correlations between insulin-like growth factor I receptor and 
oestrogen receptor beta expression in colorectal cancer tumourigenesis (Papaxoinis et al., 
2007), highlighting the use of the method for monitoring multiple markers simultaneously. 
Also, such studies highlight the applicability of such a method for oncogenic biomedical 
research purposes.  
Other successful applications of multiple immunostaining and imaging via CLSM include 
imaging mesenchymal stromal cells (MSCs) in cryosections of colonic tissue via 
immunostaining of the MSC marker CD146 alongside other non-MSC markers such as von 
Willebrand factor (vWF) and actin (Signore et al., 2012). Markers such as E-cadherin, Ksp-
cadherin and collagen IV have been visualised in FFPE sections of kidney (Robertson et al., 
2008).  In addition, whole mounts of human and murine bone marrow have been imaged via 
IF and CLSM against markers such as CD3, CD45R and Ter119 in order to visualise 
haematopoiesis in three dimensions (Takaku et al., 2010). Another study optimised a multiple 
immunolabelling CLSM method to simultaneously visualise viral antigens and tissue antigens 
to identify the foot and mouth disease virus in a wide range of animal tissues (Arzt et al., 
2009).  
 The wide range of tissues and markers that have been successfully imaged highlights the 
wide applicability of the method as a histological and pathological research tool. However, 
relatively few studies have been undertaken using similar methods to image multiple markers 
within immunological tissues. This constitutes the primary aim of this study. 
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1.8 IF CLSM for imaging immunological tissues 
Based on these recent successes of multiple marker imaging via IF and CLSM in many tissue 
types, the ability to simultaneously visualise multiple biomarkers within secondary lymphoid 
tissues would be highly beneficial to immunological histology and histopathology. This is 
because the immunophenotypes of immunological cells are complex and often require the 
identification of more than one marker for accurate identification of specific cell types (Ma et 
al., 2006). In addition, cancers that manifest themselves within lymph nodes, such as 
lymphatic leukaemias and lymphomas, have complex immunophenotypes that can confer 
diagnostic and prognostic information of the disease (Hayden et al., 2012; Sathiya and 
Muthuchelian, 2009).  
From a methodological perspective, lymphoid tissues are ideal for the optimisation of an 
IF/CLSM tissue imaging method, because they possess histologically distinct areas that 
contain high densities of immunological cells which have well defined immunophenotypes, 
such as primary and secondary follicles that contain high levels of B-lymphocytes (Cesta, 
2006; Willard-Mack, 2006). Thus, many different antigens can be chosen from, many of 
which will provide robust staining of target cells. In addition, immunological markers such as 
CD3, CD4 and B220 have already been imaged via IF and CLSM on lymphoid tissues such as 
mouse spleen with robust results (Ma et al., 2006).  
1.9 Aims and objectives 
Preliminary experiments performed on lymph node cryosections had yielded promising 
results in markers such as the CD4 and CD8 T cell subset markers, the B cell markers CD19 
and CD20 and κ and λ immunoglobulin light chain antigens (data not published). These 
studies were, however, performed using the older generation fluorophores FITC, TRITC and 
Cy5. Therefore, based on these preliminary studies and the literature discussed, the aims of 
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this study were to further refine and modernise the multiple immunostaining protocol on 
immunological tissues, and optimise the microscope imaging settings to obtain the best 
images possible. In doing this, the study will develop this method as a research tool as well as 
increase its potential for routine use in clinical histopathology. The specific study objectives 
were to: 
 Establish an effective immunological tissue type upon which to optimise secondary 
antibody dilutions. 
 Optimise the immunostaining protocol for use with new generation Alexa fluorophores. 
 Optimise the secondary antibody dilutions and confocal laser-scanning microscope 
settings to produce images with the best possible resolution and signal/noise ratio. 
1.10 Experimental procedure 
For the purposes of this optimisation study, it was decided that staining against B-lymphocyte 
surface markers within fixed tissue samples would be a suitable approach, because B cells are 
abundant within secondary lymphoid organs and tissues such as the spleen and lymph nodes 
(Cesta, 2006; Willard-Mack, 2006). Specifically, the B-lymphocyte antigens that were 
selected were the B-cell surface marker CD19, and kappa (κ) and lambda (λ) immunoglobulin 
light chains. These three antigens were chosen for a number of reasons as follows: 
 CD19 is expressed by all recognisable B-lineage cells independent of developmental stage 
and maturity, with the exception of fully differentiated plasma cells (Del Nagro et al., 
2005). B-lymphocytes also express surface immunoglobulin, which is expressed by all B 
lineage cells except for those at very early stages of development, or terminally 
differentiated plasma cells (Thiel, 1985). In secondary lymphoid organs, affinity 
maturation of B lymphocytes in response to foreign antigen takes place within secondary 
follicles (Cesta, 2006; Vandervalk and Meijer, 1987; Willard-Mack, 2006), and therefore 
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dense regions of CD19, and surface immunoglobulin expressing cells should be present, 
providing excellent regions to image for optimisation purposes.  
 All B cells produce antibodies with κ or λ immunoglobulin light chain forms, which are 
also expressed on the cell surface within IgM and IgD isotypes. Individual B cells 
exclusively express either κ or λ immunoglobulin light chain forms (Takeda et al., 1993). 
Therefore, any given CD19 positive cell should also be positive for either κ or λ antigen. 
This expectation aids the optimisation process in that a general idea of the resulting 
staining pattern is known, and it is therefore easier to discern genuine antigen staining 
from imaging artefacts.  
 Previous preliminary experiments performed on other confocal microscopy systems and 
with original fluorophores had reported that the available anti-CD19, κ and λ antibodies 
were effective. The staining was relatively bright and abundant in relation to other 
markers imaged, and therefore ideal for optimisation experiments. 
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2.0 Materials and Methods 
2.1 Acquisition and fixation of tissue samples 
All tissue samples used in the study were obtained from the Human Biomaterials Resource 
Centre at the University of Birmingham, observing all ethical guidelines. Human spleen and 
reactive lymph node tissue sections of 5 µm thickness were independently pre-prepared via 
cryosectioning and affixed to glass slides. Mounted tissue sections were fixed in acetone for 
10 minutes at 4
 o
C and stored at -20 
o
C in the presence of silica gel to prevent condensation 
and ice crystal formation within the tissue samples. 
2.2 Jenner/Giemsa staining and imaging 
Jenner/Giemsa phosphate buffer was diluted 1:25 in distilled water. Jenner stain (Raymond A. 
Lamb Ltd) was diluted 1:3 in the diluted buffer, and Giemsa stain (VWR) was diluted 1:20 in 
the diluted buffer. 50 µl diluted Jenner stain was pipetted onto the tissue sections and 
incubated for 5 minutes at room temperature (RT). The tissue was carefully washed with 
distilled water, and 50 µl diluted Giemsa stain was pipetted onto the tissue section and 
incubated for 10 minutes at RT. The dH2O wash was repeated and the tissue section left to dry 
thoroughly before mounting with DePeX mounting medium (VWR) and a 1.5 mm thick glass 
coverslip.  The stained sections were imaged at 10x magnification using an Olympus BX-40 
light microscope, an Olympus 10x Plan objective with a numerical aperture of 0.25 and an 
Olympus C-5050 Zoom Digital Camera. 
2.3 Indirect immunofluorescence staining protocol 
Glass slides with tissue sections were removed from -20 
o
C storage and left to equilibrate to 
room temperature (RT) for 10 minutes. Tissue sections were outlined using a slide marker pen 
(Dako) to keep tissue sections covered with antibody solution. To block endogenous Fc 
receptors and prevent non-specific antibody binding to immune cells, 50 µl FcR Blocker 
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(Innovex Biosciences) was pipetted onto the tissue sections and incubated for 30 minutes at 
RT within a light excluding moist chamber. Excess fluid was removed from the tissue 
sections and 50 µl primary antibody diluted in FcR Blocker was added to the tissue sections 
and incubated for 60 minutes at RT in a moist chamber. Excess solution was removed and the 
slides washed in a phosphate-buffered saline (PBS) bath for 20 minutes at RT in the dark and 
on a magnetic stirrer at low speed. Secondary antibody dilutions were prepared as stated for 
primary antibodies, but the solution was also microfuged for 2 minutes at 14,000 RPM. 
Excess PBS was removed and 50 µl secondary antibody diluted in FcR blocker was pipetted 
carefully from the top of the solution and onto the tissue sections, and incubated in the same 
manner as the primary antibody. A PBS wash was repeated as before, and excess PBS 
removed. To avoid problems with pipetting error and avoid pipetting centrifuged secondary 
antibody aggregates at the base of the eppendorf tubes, all antibody solutions were made up to 
volumes of at least 50 µl excess. Stains against multiple antigens were performed by diluting 
all primary antibodies of individual IgG subclass within one mixture, followed by the same 
process with secondary antibodies. To control for non-specific binding of fluorophore-
conjugated secondary antibodies, the staining procedure was carried out twice for each 
variation of staining, but for the second stain the primary antibody was omitted. 
2.4 Nuclear counterstaining and slide mounting 
Two mounting and counterstaining methods were used within the study. For slides mounted 
with VECTAShield with 4',6-diamidino-2-phenylindole (DAPI, Vector Laboratories),  slides 
were mounted and counterstained by pipetting 10 µl VECTAShield with DAPI onto the tissue 
section and placing a glass coverslip onto the section. The slides were then inverted on tissue 
paper to remove excess mountant. Coverslips were sealed around the edges with clear nail 
varnish. Alternatively, tissue sections were counterstained by incubation in a PBS solution 
with Hoechst bis-benzimide dye 33258 at 20 µg/ml for 1 minute at RT, followed by a 1 
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minute PBS wash. Slides were then mounted by pipetting 10 µl glycerol-based antifade 
mounting medium (INOVA Diagnostics), and inverted on tissue paper to remove excess 
mountant and sealed with clear nail varnish. Prior to imaging, the slides were then stored at -
20 
o
C in the dark. 
2.5 Primary and secondary antibody tables 
 Due to issues of cross-reactivity, it can be potentially difficult to image multiple markers 
simultaneously using multiple primary antibodies raised in the same animal. One solution is 
to use monoclonal primary antibodies of differing antibody subclass, and corresponding 
monoclonal secondary antibodies highly specific to these subclasses (Buchwalow et al., 2005; 
Ma et al., 2006), which was used for this study.  
The following antibodies were used throughout the study. All primary and original secondary 
antibodies were supplied by Santa Cruz Biotechnology, and all Alexa secondary antibodies 
were supplied by Invitrogen: 
Primary Antibodies 
Isotype 
Subclass 
Affinity Stock 
Concentration 
Dilution Used 
IgGγ1  mouse anti-human κ 
Immunoglobulin light chain 
100 µg/ml 1:100 (1 µg/ml) 
IgGγ2a mouse anti-human λ 
Immunoglobulin light chain 
100 µg/ml 1:50 (2 µg/ml) 
IgGγ2b  mouse anti-human CD19 100 µg/ml 1:100 (1 µg/ml) 
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The primary and first generation secondary antibodies were used at fixed dilutions determined 
as optimum concentrations by preliminary experiments. However, Alexa secondary antibodies 
were used at different dilutions depending on the experiment, as detailed in the results section. 
Alexa fluorophore - conjugated secondary antibodies 
Subclass 
Affinity 
Fluorophore, affinity and isotype Stock 
Concentration 
Dilution Used 
γ1 Alexa488 conjugated goat anti-
mouse IgG γ1 
2 mg/ml See results 
γ2a Alexa568 conjugated goat anti-
mouse IgG γ2a 
2 mg/ml See results 
γ2b  Alexa647 conjugated goat anti-
mouse IgG γ2b 
2 mg/ml See results 
 
For the dilutions stated in the following results sections, the corresponding final 
concentrations for the Alexa secondaries were as follows (table over page): 
Original fluorophore - conjugated secondary antibodies 
Subclass 
Affinity 
Fluorophore, affinity and isotype Stock 
Concentration 
Dilution Used 
γ1 FITC conjugated goat anti-mouse 
IgG γ1 
1 mg/ml 1:100 (10 µg/ml) 
γ2a TRITC conjugated goat anti-mouse 
IgGγ2a 
1 mg/ml 1:50 (20 µg/ml) 
γ2b  Cy5 conjugated goat-anti mouse  
IgG γ2b 
1 mg/ml 1:100 (10 µg/ml) 
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Dilution Concentration 
1:50 40 µg/ml 
1:100 20 µg/ml 
1:200 10 µg/ml 
1:400 5 µg/ml 
 
For additional information regarding the molecular and spectral properties of each 
fluorophore used within this study, see table S1. 
2.6 Confocal laser scanning fluorescence microscopy imaging 
For all experiments, a Nikon A1R
+
 Eclipse Ti Inverted Microscope System (Nikon 
Instruments) was used, and images were digitally acquired through photomultiplier tubes via 
Galvanometric one-way laser scanning at a speed of 1 frame per second and a resolution of 
512x512 pixels. Images were acquired at 40x magnification, for which an oil immersion 40x 
Plan Fluor differential interference contrast (DIC) H N2 objective with a numerical aperture 
of 1.3 was used (Nikon). Fluorescence images for up to 4 colours were simultaneously 
captured, with electronic sequential laser scanning enabled to aid elimination of spectral 
bleedthrough. Confocal Pinhole diameter was preset to 1 Airy Unit. Laser excitation and 
emission filter settings are detailed in the following table: 
Photomultiplier Channel Laser Excitation Wavelength 
(nm) 
Emission Collection Window 
(nm) 
DAPI/Hoechst 33258 402.1 425-475 
FITC/Alexa 488 488 500-550 
TRITC/Alexa 568 561.1 570-620 
Cy5/ Alexa 647 637 662-737 
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Areas of high B lymphocyte levels with strong CD19 positivity were preferentially imaged, 
and for each individual tissue section the corresponding region or a highly similar region was 
imaged and analysed for continuity. 
2.7 Image analysis 
Images were analysed using NIS-Elements v3.2 (Nikon). The linear contrast was adjusted on 
the final images to emphasise stained areas and remove background noise. This value differed 
per image and tissue section, but corresponding secondary only controls were always 
examined under the same look-up table (LUT) settings to confirm that no background or 
autofluorescence was emphasised, or indeed at all present. 
2.8 Quantification of CD19 and κ/λ positive cells 
Three images of suspected B-lymphocyte rich regions were taken at 40x magnification from 
lymph node cryosections stained with differing secondary antibody panels. For consistency, 
areas that were imaged contained CD19 positive cells throughout the entire image field. All 
cells that were CD19 and κ-antigen positive were counted, as were CD19 and λ-positive cells. 
The numbers were averaged for each differing antibody panel, and the standard deviation and 
standard error of the values were obtained using Microsoft Excel 2007.  
2.9 Statistical analysis 
Two-tailed T tests were performed between each variation of secondary antibody staining 
panel using Microsoft Excel 2007. 
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3.0 Results 
3.1 Selection of suitable tissue and mounting method 
 
 
 
 
 
 
 
 
 
 
Firstly, the primary tissue samples for which to perform the optimisation experiments on had 
to be determined. To establish this, tissues were simultaneously stained with pre-determined 
concentrations of previously used original secondary fluorophore conjugates, because they 
were known to be effective (See section 2.5).  Initially, the experiments were performed on 
spleen biopsy samples from healthy subjects. However, the first spleen sample analysed did 
not produce good quality staining, and it was difficult to positively identify stained cells (fig.4 
Figure 4 – Example images of staining quality across immunological tissue samples. A. Healthy spleen cryosection. B. 
Healthy spleen cryosection from a different individual. C. Reactive Lymph node cryosection. Images were obtained at 
40x magnification and scale bars represent 50 µm. Pseudocolours – Blue = Nuclear counterstain, Green = κ/FITC, orange 
= λ /TRITC, red = CD19/Cy5. 
A
C
B
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Figure 5 - Jenner/Giemsa stains of healthy spleen (A) and reactive lymph node (B) cryosections at 10x magnification. 
Nuclei stain blue, while eosinophils stain in varying shades of pink. The densely packed darker regions visible on the 
reactive lymph node stained strongly for CD19 and κ/λ antigen, suggesting that they were B-lymphocyte rich regions, 
while it was difficult to identify B-lymphocyte rich regions in the spleen samples.  
A). In addition, the sample contained relatively few B-lymphocyte rich follicular regions or 
germinal centres. The staining protocol was therefore repeated with cryosections from a new 
spleen sample, which also showed poor staining quality (fig. 4B), and it was therefore decided 
to test the protocol on cryosections derived from hyperplasic reactive lymph nodes.  Reactive 
lymph nodes are enlarged and generally richer in B-lymphocytes as they are actively 
responding to antigen stimulation (Bain and Bain, 1985). The quality of staining was 
observed to be superior to either spleen sample tested, and positively stained cells were far 
easier to identify and more abundant (fig. 4 C). Jenner-Giemsa stains were also performed on 
the tissues to examine the histological differences between the lymph node cryosections and 
reactive lymph node cryosections (fig. 5). Within the reactive lymph node cryosections, it 
proved difficult to identify any well defined histological features that are known to contain a 
high proportion of CD19 positive B-lymphocytes such as germinal centres. However, darkly 
stained regions as seen in fig. 5B corresponded with CD19 positive areas when imaged with 
the confocal microscope suggesting that these regions were rich in B lymphocytes. These 
areas were abundant throughout the tissue, and it was therefore decided that all subsequent 
experiments were to be carried out on reactive lymph node cryosections. 
A B
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 Another potential issue was the quality of the nuclear counterstain. It was observed that the 
relative brightness of the Hoechst nuclear counterstain was faint, meaning that the laser power 
and PMT gain of the Hoechst channel had to be set high to obtain quality images. A different 
counterstaining and mounting method was therefore tested. VECTAShield with DAPI is 
another glycerol based mountant that remains fluid after mounting, but unlike the previously 
used mountant it also contains the counterstain dye (DAPI), removing the requirement for the 
Hoechst staining step. However, there was little difference in counterstaining brightness 
between both methods (fig. 6). Furthermore, the brightness of Cy5 staining was markedly 
diminished when the slides were mounted with VECTAShield. The original Hoechst 
counterstaining method was therefore used for all subsequent experiments rather than 
VECTAShield with DAPI.   
 
 
Figure 6 – Comparison of Cy5 signal strength between tissue sections mounted with INOVA antifade mounting 
medium and counterstained with Hoechst 33258 (A) and VECTAShield with DAPI (B). Cy5 signal strength was much 
stronger in the first instance, which was therefore used for all subsequent experiments. Images were obtained at 40x 
magnification and scale bars represent 50 µm. Pseudocolours - Blue = nuclear counterstain, red = CD19/Cy5. 
 
A B 
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3.2 Acquisition of microscope settings and single colour controls 
The next stage of the study was to identify the optimal laser power and photomultiplier tube 
(PMT) gain settings for maximum signal strength, and to determine that no spectral 
bleedthrough was occurring between the lasers lines used to visualise each different 
fluorophore. As previously discussed, this can potentially manifest as a problem where 
multiple fluorophores are used simultaneously, thus it was essential to confirm that this was 
not occurring. 
When acquiring the images, it was also important to avoid fluorophore and detector 
saturation. Fluorophore saturation can occur if the laser power is set too high, causing all 
fluorophores to excite throughout the z-plane, resulting in unnecessary photobleaching and 
poorer z-axis resolution (Brown, 2007) . Alternatively, detector saturation can occur if the 
PMT gain is set too high, leading to a loss of features within the sample and false 
interpretation of images (Brown, 2007). To avoid either of these scenarios, a saturation 
detector feature was enabled during these experiments, which highlights fully saturated pixels 
within the image, thereby allowing for the adjustment of microscope settings accordingly. 
To establish these settings, and if spectral bleedthrough was present, individual lymph node 
cryosections were stained with one primary and a fluorophore-conjugated secondary antibody 
of corresponding isotype subclass specificity, and imaged in turn. The following laser power 
and PMT gain settings at which the images were collected were chosen on the basis of giving 
the strongest signal on positively labelled samples without saturation, whilst having no 
observable signal present in the corresponding channel for the control tissue sections stained 
with secondary antibody only (table over page): 
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Spectral Channel Laser Power PMT Gain 
Hoechst/DAPI 50% 110 
FITC/A488 30% 70 
TRITC/A568 30% 70 
Cy5/A647 50% 95 
 
 Images were obtained for all four collection windows, and if no spectral bleedthrough was 
occurring, all channels were expected to be free of signal except for the intended channel of 
the fluorophore the sample was stained with. Some residual signal was occasionally present in 
the Hoechst channel (fig. 7), but this was due to the fact that the Hoechst counterstain was 
relatively faint and it was therefore necessary to set PMT gain and laser power relatively high. 
This was therefore most likely to be tissue autofluorescence as the signal covered all tissue 
present in the image and did not resemble staining observed in any other channel. Because 
this tissue autofluorescence was present in the Hoechst channel, this did not pose a problem 
for the analysis of the fluorophore-conjugated secondary antibodies and was therefore not an 
overbearing concern.  
Aside from the Hoechst imaging channel, all secondaries produced signal in the correct 
imaging channel, and no signal was observed across multiple channels (fig. 7). The PMT gain 
and laser power settings at which these images were obtained could therefore be used for all 
other experiments with the assurance that spectral bleedthrough was not disrupting the 
interpretation of the images. To be confident of this throughout future experiments, these 
settings were treated as maximum and not exceeded. 
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Figure 7 –  Single colour controls for all fluorophores used in the study performed on reactive 
lymph node cryosections. Aside from tissue autofluorescence detected in the Hoechst channel, no 
detectable signal was observed in channels other than those for which the corresponding primary 
antibody was added. Images were obtained at 40x magnification and scale bars represent 50 µm. 
Pseudocolours -  Blue = nuclear counterstain, Green = κ /FITC or A488, orange = λ /TRITC or 
A568, red = CD19/Cy5 or A647. 
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3.3 Titration of Alexa-conjugated secondary antibodies 
It was established that no spectral bleedthrough was occurring across laser lines for any 
fluorophore type used in this study when used at the highest concentrations, and  imaged with 
the highest laser power and PMT gain settings possible without saturation.  The next phase of 
the study was to identify the optimum dilutions at which to use the Alexa secondaries along 
with the full cohort of primary antibodies. This was achieved via titration of the secondary 
antibodies through 1:2 serial dilutions, ranging from overall dilutions of 1:50 to 1:400, and 
qualitatively assessing the brightness and signal/noise ratio in relation to the original 
secondaries. In addition, negative controls treated with secondary antibody only were 
performed for each dilution to assess the levels of nonspecific flourophore binding to the 
tissue and adjust the microscope settings accordingly.  
Alexa488 was most effective at a dilution of 1:200, because at 1:50 and 1:100, a large amount 
of non-specific signal was present within the secondary only control. The laser power and 
gain levels were therefore reduced so that this signal was no longer visible, but this had the 
effect of reducing the overall brightness of the staining to unacceptable levels (fig. 8). At 
1:400, the staining appeared fainter than that of 1:200 using the settings described in section 
3.2 for visualising A488, and these settings were not exceeded because: 
 a) tissue autofluorescence was visible at laser power and PMT gain settings that were slightly 
higher than optimum levels.  
b) the single colour controls had indicated an absence of spectral bleedthrough at these 
settings, and this was no longer a reliable observation should the laser power or PMT gain be 
increased. 
Alexa568 produced high quality staining at dilutions of 1:50, 1:100 and 1:200, while the 
signal was slightly fainter at 1:400 (fig. 8). Although 1:100 and 1:200 were effective, 1:50 
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was deemed to be the optimum concentration due to very little nonspecific signal detected in 
the secondary only control and slightly superior signal strength. 
Alexa647 was deemed to be most effective at 1:400 because at levels of 1:50, 1:100 and 1:200 
there were high levels of background noise in the secondary only controls, suggesting a high 
level of nonspecific fluorophore binding. However, at 1:400, A647 was faint compared with 
Cy5 at 1:100 and the linear contrast had to be enhanced more to reveal the staining (fig. 8). As 
the contrast was enhanced, the same alterations were performed on the secondary only 
controls to ensure that no tissue autofluorescence or nonspecific fluorophore binding was 
enhanced. 
Overall, it was qualitatively determined that A488 at 1:200 and A568 at 1:50 provided 
brighter staining than FITC at 1:100 and TRITC at 1:50. However, due to high levels of 
nonspecific noise at higher concentrations, the optimum dilution of A647 was 1:400 at which 
the signal levels were relatively low, and the most effective far-red emitting fluorophore was 
therefore less apparent. Thus, the next stage of the study was to perform triplet stains of 
CD19, κ and λ antigens, using the Alexa secondaries at the optimally defined dilutions and 
directly comparing the staining quality to the optimal original secondary antibody panel.  
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Figure 8 – Reactive lymph node cryosections stained with the full cohort of primary antibodies 
and subsequent serial titrations of Alexa fluorophore conjugated secondary antibodies performed 
to obtain optimum dilutions. Images were obtained at 40x magnification and scale bars represent 
50 µm. Pseudocolours – Blue = nuclear counterstain, Green = κ /A488, orange = λ / A568, red = 
CD19/ A647. 
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3.4 Identification of optimum secondary antibody concentrations 
Due to a shortage of tissue sections, the following experiments were carried out on reactive 
lymph node sections sourced from a different patient. However, highly similar staining 
characteristics were observed, and thus the information obtained from the previous 
optimisation experiments could be confidently applied to these subsequent experiments 
performed on reactive lymph node tissue obtained from another individual. This 
reproducibility of staining quality between individuals was also in itself an important 
observation as this is an essential quality should the method be routinely used in 
histopathology. 
The next stage of the study was to obtain images of lymph node cryosections stained against 
CD19, κ-antigen and λ-antigen using previously determined optimum dilutions of Alexa 
conjugated secondary antibodies (fig. 9C). Additionally, staining was performed using 1:100 
Cy5 rather than 1:400 A647 for a direct comparison between the two fluorophores when used 
alongside the optimal dilutions of the other Alexa fluorophores (fig. 9B). A stain was also 
performed using the original secondary antibody panel for direct comparison (fig. 9A). 
As expected, when both optimum concentrations of antibody sets were directly compared, 
A488 and A568 were brighter than FITC and TRITC respectively (fig. 9). 1:100 Cy5 was 
brighter than A647 overall, and the contrast had to be adjusted for A647 to be observable. To 
evaluate the effectiveness of the staining, the levels of CD19 and κ-positive cells were 
compared against CD19 and λ-positive cells. The values obtained were generally consistent 
across all three staining methods, and two-tailed T tests performed between each secondary 
antibody set indicated no statistically significant differences (A vs. B P = 0.69, A vs. C P = 
0.97, B vs. C P= 0.54, fig. 9 D/E). The average κ/λ ratio across all stains was 1.65 (SEM = 
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±0.81, range = 1.3-1.98, fig.9 E) suggesting that all of the secondaries used were accurately 
representing the B cell κ/λ ratio present in the sample.  
The evidence that these concentrations of A488 and A568 were more effective than the 
optimal concentrations of the corresponding original fluorophores was fairly conclusive, but 
Cy5 was observed to be brighter than A647 at their corresponding optimal dilutions. 
However, upon adjustment of linear contrast, the signal strength of A647 could be made more 
pronounced, and making the same adjustments to images of secondary only controls made 
sure that no autofluorescence or background staining was also being emphasised. When this 
was performed, similar staining patterns were observed using each fluorophore (Fig 9 D, E), 
implying that A647 still produced adequate staining brightness for the resolution of CD19 
positive cells, albeit not as bright as Cy5. Thus, the optimum secondaries were determined as 
follows:  
Corresponding primary 
antibody antigen specificity 
Optimum original 
secondary conjugate 
Optimum Alexa secondary 
conjugate 
κ 1:100 FITC 1:200 A488 
λ 1:50 TRITC 1:50 A568 
CD19 1:100 Cy5 1:400 A647 
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Figure 9 – Optimised staining panels. A. 1:100 FITC, 1:50 TRITC, 1:100 Cy5. B. 1:200 A488, 1:50 A568, 1:100 Cy5. 
C. 1:200 A488, 1:50 A568, 1:400 A647. Images were obtained at 40x magnification and scale bars represent 50 µm. 
D. Relative levels of CD19 and κ-light chain positive cells vs. CD19 and λ-light chain positive cells across the three 
differing secondary antibody panels. E. Relative κ/λ Ratios of CD19 positive cells across the three differing secondary 
antibody panels. For both graphs, three images were analysed per antibody panel for a total of nine images for the total 
average, and error bars represent the standard error of the mean. Pseudocolours – Blue = nuclear counterstain, Green = 
κ /FITC or A488, orange = λ /TRITC or A568, red = CD19/Cy5 or A647. 
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4.0 Discussion 
This study has developed and optimised a method for the simultaneous visualisation of CD19, 
κ and λ immunoglobulin light chain antigens in reactive lymph node cryosections using a 
combination of immunofluorescence and confocal laser scanning microscopy. The images 
obtainable with this method are of high quality and resolution, and allow for the visualisation 
of three specific biomarkers alongside a nuclear counterstain. The study developed on 
preliminary experiments that used older generation fluorophores and optimised the method for 
use with new generation Alexa fluorophores. The increase in photostability, and in the case of 
A488 and A568 signal brightness, gained from using these fluorophores increases the 
viability of the staining method to imaging via CLSM (Berlier et al., 2003; Panchuk-
Voloshina et al., 1999; Robertson et al., 2008), as well as increases the clinical applicability of 
the method due to greater re-imaging and long-term storage capabilities (Robertson et al., 
2008). The method also provides superior multiple marker imaging capability in comparison 
to widely used enzyme-based immunohistochemical methods (Robertson et al., 2008).   
4.1 The establishment of effective tissues and mounting methods 
This study originally intended to carry out the optimisation experiments on healthy splenic 
tissue rather than reactive lymph node. However, staining was of poor quality and sparse. This 
could have been due to antigen epitope deterioration, but cryosectioning and acetone fixation 
generally preserves antigens to a high standard (Hofman, 2009; Ripper et al., 2008), and 
reactive lymph nodes were processed in the same manner. Alternatively, the tissue sections 
may simply have been low in B-lymphocyte rich regions.  Regardless of the cause, this 
setback further highlighted the importance of good quality tissue sections for imaging. 
In addition, locating these apparently sparse regions of tissue that should be rich in B 
lymphocytes, such as primary and secondary follicles (Cesta, 2006), was difficult due to some 
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technical aspects of the microscope used for the study. The microscope was equipped with a 
10x air immersion objective, unlike the 40x objective which was oil immersion, causing a 
number of problems.  Firstly, the light collection capability of this objective was sub-standard 
in comparison with the oil immersion objective, causing difficulty in resolving any 
fluorescent signal at 10x magnification. Secondly, as the 10x objective was air immersion and 
the 40x objective was oil immersion, the differing refractive indices of the two mediums 
meant that it would have been difficult to optimise multiple microscope settings and antibody 
dilutions that would produce high quality images for each objective type.  All in all, the 
splenic tissue was not conducible to experiments where high levels of staining were required 
to evaluate the effectiveness of secondary antibody dilutions and microscope settings. The 
reactive lymph node samples produced high quality staining of CD19, κ and/or λ light chain 
antigen positive cell regions which were abundant throughout the tissue, allowing for 
relatively simple location at 40x magnification. A higher number of images per tissue section 
could also be obtained. Future experiments could involve both 10x and 40x oil immersion 
objectives, avoiding these problems, as 10x images are also highly useful for obtaining a more 
general overview of the distribution of biomarkers within the tissue. 
The Hoechst nuclear counterstaining dye was relatively faint, but mounting slides using 
VECTAShield with DAPI resulted in Cy5 signal amelioration. VECTAShield was initially an 
attractive option because it was more time effective - the inclusion of DAPI within the 
mounting medium removed the necessity for a counterstaining step. The loss of Cy5 signal 
was unexpected, but may have been caused by the fact that VECTAShield contains the 
antifade compound p-phenylenediamine (PPD). As stated by the VECTAShield data sheet, 
PPD cleaves the cyanine molecules in Cy2 fluorophores and thus ameliorates the fluorescent 
signal, which may also have occurred with the Cy5 fluorophores used in this study. Any 
future studies featuring cyanine dyes should therefore avoid mounting mediums that contain 
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PPD. Overall, the low signal strength of the Hoechst counterstain was a minor inconvenience 
rather than a major problem because the laser power and PMT gain could be increased in 
compensation. This did result in some tissue autofluorescence in the Hoechst/DAPI channel, 
but not sufficiently to hinder the interpretation of the images. 
4.2 The value of experimental controls 
The single colour control experiments were essential to assume that any signal observed in a 
given emission collection channel was not caused by spectral bleedthrough across channels. 
In addition, performing secondary only stains alongside all experiments allowed for the 
determination of the concentration at which non-specific fluorophore binding was minimal 
while true staining was strong. Together, these controls greatly increased the viability of the 
images and allowed for the determination of optimum antibody dilutions and microscope 
settings. 
Although the controls employed in this study were deemed adequate, an antibody isotype 
subclass control may also have granted even further confidence in the images obtained. 
Antibody isotype subclass controls confirm that the secondary antibodies are exclusively 
recognising the primary antibody isotype subclass intended. This is achieved by sequentially 
replacing primary antibodies with the same concentration of a nonspecific isotype control 
antibody of the same species and isotype subclass (Robertson et al., 2008). However, this was 
deemed as unnecessary for this study, mainly because each individual fluorescent secondary 
used produced staining patterns against their corresponding anti- CD19, κ or λ primary 
antibodies as would be expected for these antigens. 
4.3 Optimum antibody dilutions 
Based on signal/noise observations, it was eventually established that the optimum dilutions 
of Alexa conjugated secondary antibodies were 1:200 for A488, 1:50 for A568 and 1:400 for 
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A647. However, 1:100 Cy5 was qualitatively observed to produce better signal than 1:400 
A647, the highest concentration determined to be viable due to high background signal. 
Nevertheless, it was decided that A647 was a superior choice to Cy5 for a number of reasons:  
a) A647 signal strength could be amplified by adjusting the linear contrast within ranges that 
did not exaggerate background staining levels, producing statistically indifferent CD19 
staining patterns to Cy5.  
b) Cy5 was shown to destabilise when mounted with VECTAShield, meaning that it is less 
adaptable to methodological variations. 
c) Like Alexa488 compared with FITC and Alexa568 compared with TRITC, Alexa647 has 
been shown to be more photostable in comparison to Cy5, and is therefore more conducive to 
the high intensity laser excitation methods of CLSM and sample storage and reimaging 
capability (Berlier et al., 2003; Panchuk-Voloshina et al., 1999; Robertson et al., 2008).  
However, while Alexa fluorophores are reportedly more photostable, it may be beneficial for 
future experiments to quantify the photostability of the dyes when used in this histological 
context for staining immunological tissues. For example, Alexa-stained tissues could be 
exposed to set laser intensities for set time periods, and the change in signal intensity 
quantified and compared with those of the original dye-conjugated secondaries exposed to the 
same conditions. Fluorophore stability during storage of immunological tissue cryosections 
could also be assessed by imaging immediately after staining and mounting and comparing 
fluorescence signal strength after storage for set time periods, as this is likely to differ 
between tissue processing methods and tissue types. 
Overall, images obtained from these optimum dilutions of Alexa conjugated secondaries were 
qualitatively determined as sharp and showing a good signal/noise ratio for each fluorophore. 
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Cells that were CD19 positive were also either κ or λ-light chain positive, and there was very 
little colocalisation of κ-antigen and λ-antigen signal, as would be expected (Takeda et al., 
1993). The use of Alexa fluorophores is also beneficial from an economic perspective - while 
Alexa conjugated secondary antibodies can be slightly more expensive than older generation 
fluorophore conjugates, this study demonstrates that higher dilutions of Alexa secondaries can 
be used in comparison with the original secondaries. In the case of A488 and A568, a better 
signal/noise ratio was observed, and although the final working dilution of A568 was 1:50, 
only a very slight drop in staining quality was observed in dilutions up to 1:200 suggesting 
that A568 could be reliably used at these lower dilutions. Had there been no time constraints, 
certain parameters of the staining protocol could also have been adjusted to obtain the best 
possible signal/noise ratios, such as the incubation times of the primary and secondary 
antibodies, or adding gentle movement/vibration to the incubation steps, which has been 
shown to improve signal/noise ratio in other IF applications (Jacobsen and Staines, 2004). It 
was however relatively simple to distinguish and remove background noise from true 
staining, and the incubation methods used were therefore adequate for the purposes of this 
study.    
Quantitative analysis revealed that the ratio of CD19/κ-positive cells against CD19/λ-positive 
cells was highly similar for all secondary antibodies assessed. This was an important 
observation, as firstly it indicated that the staining patterns observed were likely to represent 
the true B-lymphocyte κ/λ light chain ratios of the tissue. Secondly, the fact that all 
combinations of fluorophores generated the same pattern of staining was further evidence that 
all secondaries were binding to the correct primary antibody isotype subclasses. In addition, 
the observed average κ/λ ratio of 1.65 was fairly normal for a non-diseased reactive lymph 
node - one study into the κ/λ ratio of B-lymphocytes within reactive lymph nodes recorded an 
average κ/λ ratio of 1.78 in germinal centre cells and 1.56 in mantle cells (Reichard et al., 
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2003). Although the markers imaged in this study could not distinguish germinal centre cells 
from mantle cells, both values are similar, further implying that the staining was correct. If 
more time had been available, flow cytometric analysis could have been performed on the 
tissue samples used to further support these observations. Additionally, although the standard 
error values were relatively small and staining characteristics were reproducible throughout 
the study, the quantification experiments could have been repeated for increased confidence in 
the results obtained. 
4.4 Potential future applications of IF multilabelling and CLSM imaging for 
immunological tissues 
This study has optimised a relatively simple method of simultaneous spatial resolution of 
multiple antigens within lymphatic tissue. Not only is this tool valuable for research into the 
molecular mechanisms of normal immunological processes as well as disease, but it could 
potentially be applied in a clinical setting to diagnose and establish prognoses and suitable 
treatment courses of cancers based on their individual molecular profiles determined through 
immunophenotyping. In comparison to flow cytometry, CLSM immunophenotyping is lower 
throughput, but information concerning the spatial distribution of multiple markers within the 
tissue is obtainable within two or three dimensions, which is not possible with flow cytometry 
(Demandolx and Davoust, 1997; Robertson et al., 2008; Takaku et al., 2010).  
The main reason for using primary antibodies specific to CD19, κ and λ antigens was that 
such staining should follow an expected pattern and the primary antibodies were known to be 
effective. However, the simultaneous imaging of these markers in a lymph node cryosection 
may still assist in the diagnosis of many B cell neoplasms. An abnormal κ/λ light chain ratio 
that is heavily skewed towards one subtype is often indicative of mature B-cell neoplasms, 
because this indicates the presence of a monoclonal population of cells (Reichard et al., 2003; 
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Stahlberg et al., 2003). However, aside from these direct benefits, the true potential of the 
method will be realised as it is optimised for visualising more antigens within both healthy 
and diseased tissues. 
4.5 The potential of CLSM imaging in diagnostic and prognostic immunohistopathology 
Potential applications of the method include clinical immunophenotyping of lymphomas and 
lymphatic leukaemias for diagnostic and prognostic reasons, as well as for personalised 
treatment options. For example, B-cell chronic lymphocytic leukaemia (B-CLL) tumour cells 
resemble small, mature, monoclonal B-lymphocytes. Distinct tumour biomarkers include a 
high expression of CD5 and CD23, and forms that express CD38 and/or CD49d correlate with 
an aggressive disease course and a poor prognosis (Del Poeta et al., 2001; Hamblin et al., 
1999; Hayden et al., 2012; Pittner et al., 2005). Thus, using this IF imaging method against 
these antigens, diagnostic and prognostic markers could theoretically be identified 
simultaneously, and treatment courses could be planned based on the outcome of such 
analysis. Non-Hodgkin lymphomas are also excellent disease candidates that may benefit 
from this method. Many different forms of lymphoma exist, all of which have different 
disease courses, prognoses and treatment regimens. The histological features of lymphomas 
are well defined, but many different forms are histomorphologically similar, as well as 
appearing similar to reactive rather than diseased lymph node tissue. Thus, other such markers 
that may be beneficial to image include CD20, as 95% of malignant lymphomas as well as B-
CLL express CD20 (Sathiya and Muthuchelian, 2009). Another example includes CD134, a 
marker that can differentiate similar T-cell lymphoma types, as tumours consisting of 
activated CD41 T cells express this marker while other forms such as small T cell lymphomas 
do not, aiding in the subclassification of peripheral T-cell lymphomas (Jones et al., 1999). 
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The markers discussed in this section are but a few examples, and theoretically any 
combination of cell surface markers can be imaged simultaneously to diagnose specific 
variants of many immunological disorders. Furthermore, as well as the identification of such 
markers, the method itself could also be very important in the study of the molecular 
mechanisms that constitute the underlying cause of such markers featuring in disease. 
4.6 The potential of CLSM imaging in cancer research 
The method could also greatly benefit biomedical research into lymphomas and lymphatic 
leukaemias, through investigating the molecular mechanisms of cancers and thereby 
developing novel, personalised and targeted therapies. Such therapies target the specific 
molecular processes that cause oncogenicity, and are therefore highly effective at tumour 
killing whilst less toxic to non-neoplastic cells in comparison to methods such as traditional 
radiotherapy and chemotherapy. Cancer cells survive and proliferate due to specific mutations 
to oncogenes and/or tumour suppressor genes, which result in disrupted regulatory networks, 
aberrant responses to stress signals, and signals from the microenvironment. Resulting effects 
may include deregulated cell cycle progression and hence increased proliferation, a lack of 
response to DNA damage signals and further accumulation of mutations, and defective 
apoptotic responses and thus increased tumour survival (Sawyers, 2004). 
For several lymphatic leukaemias and lymphomas, the focus in developing such therapies has 
recently been on targeting the tumour microenvironment, or niche. B-CLL, for example, has 
no outright cure, and current therapies induce transitory remission by periodically reducing 
the load of peripherally circulating quiescent tumour cells (Chiorazzi et al., 2005; Damle et 
al., 1999). B-CLL cells that are present in tumour microenvironments within bone marrow 
and lymph node pseudofollicles are thought to be major causes of relapse due to their 
resistance to treatments and subsequent ability to restore tumour load levels, and therefore 
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specific therapies are required for targeting these cells within the tumour microenvironment 
(Hayden et al., 2012).  
As is true for normal B-cell development, CD4
+
 T helper cell interaction is thought to be 
heavily involved in B-CLL, for providing protection against apoptotic signals and promoting 
cell survival through molecular processes such as CD40-CD40 ligand interactions (Ghia et al., 
2002; Hayden et al., 2012). Stromal cell interaction could also be important, preventing 
apoptosis through modulation of the PI3K/PTEN signalling cascade (Shehata et al., 2010) and 
molecules such as VCAM-1, the cell adhesion molecule, and VLA-4 are thought to play large 
roles in the trafficking of B-CLL tumour cells to these microenvironments (Hartmann et al., 
2009). The CD38 molecule is also thought to be an important mediator of such processes, 
which correlates with the fact that it is a negative prognostic indicator for B-CLL (Deaglio et 
al., 2006). These examples are but a few of the many cell types and molecules thought to 
contribute to this highly complex niche system, and similar mechanisms of niche involvement 
are thought to be highly important in many other lymphatic diseases, such as follicular 
lymphoma  (Pangault et al., 2010). These examples therefore underlines the value of an 
imaging method that can simultaneously visualise multiple markers and provide information 
on the complex network of interactions of such cells and molecules, with the eventual goal of 
producing specific therapies that may target such molecular processes. 
To analyse these inferred specific molecular interactions in more detail, the imaging method 
could also be further developed for novel experimental applications such as Fӧrster 
Resonance Energy Transfer (FRET). This requires the use of two fluorophores with 
overlapping emission and excitation spectra, so a photon emitted from an excited donor 
fluorophore can subsequently excite an acceptor fluorophore to emit a photon (Jiang et al., 
2008; Li et al., 2000). Fluorophore crosstalk is usually undesired for multiple marker imaging, 
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but in the case of FRET it can signify molecular interactions. The sample is illuminated with 
the excitation wavelength of the donor fluorophore only, and if photons emitted from the 
acceptor fluorophore are detected, FRET has occurred. The detection of this quantum physical 
phenomenon can indicate molecular interactions because the energy transfer can only occur 
within close molecular proximity (<100 Å) (Li et al, 2000).  
4.7 Conclusions and future perspectives 
The examples of potential applications of this multiple marker imaging method via IF and 
CLSM presented in this section are but a small fraction of the overall potential of this method 
in biology and medicine. Future experiments should broaden the range of markers that can be 
imaged by optimising staining protocols for many biomarkers that have significant roles in 
immunology and immunopathology. Further continuations of this study could also involve 
optimisation for many different tissues, immunological or otherwise, as this method offers 
much for many histological applications other than immunology and immunopathology. 
Furthermore, future studies could also look to broaden the number of markers that can be 
simultaneously imaged, as has been previously accomplished by novel immunolabelling 
methods, although this can be limited by the availability of spectrally distinct fluorophores 
(Ma et al., 2006). Novel image analysis methods have been employed in an attempt to work 
around this, however such as colour addition (Ma et al., 2006; Ma et al., 2007). It may also be 
beneficial to future optimisation studies to devise quantification methods for signal/noise ratio 
rather than qualitative visual analysis as performed in this study, such as calculating the 
signal/noise ratio by comparing average gray levels of stained areas against background areas, 
or direct comparisons of pixel intensity values (Jacobsen and Staines, 2004). 
By optimising staining and imaging methods for the visualisation of CD19, κ and λ antigen in 
reactive lymph node tissue, this study has provided a basis upon which to further develop and 
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refine IF imaging via CLSM in immunological tissues as well as others, so that it may be 
applied to many diseases in both clinical histopathology and biomedical research. 
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Appendix 
Fluorophore Molecular 
Weight 
Absorption/Emission 
Maxima (nm) 
Extinction 
Coefficient 
 (L mol
-1
 cm
-1
) 
Quantum 
Yield 
FITC 389 494/518 78,000 ~0.9* 
TRITC 479 541/572 100,000 ~0.35* 
Cy5 792 650/670 250,000
†
 0.27
†
 
Alexa488 643 495/519 71,000 0.92 
Alexa568 792 578/603 91,300 0.69 
Alexa647 ~1300 650/665 237,000 0.33 
 
 
 
 
 
 
 
Table S1 - Relevant spectral information of all fluorophores used in the study.  Alexa fluorophore information was 
obtained from Invitrogen product data sheets, and other information was obtained from Thermo Scientific product data 
sheets unless otherwise stated. These values are provided for guidance only. It is important to note that the quantum 
yield of fluorophores can be reduced upon conjugation to other molecules due to fluorophore quenching or pH 
conditions, although Alexa fluorophores are less susceptible to this compared with original fluorophores as explained 
in the text.  
These measurements were obtained from dye molecules in aqueous solutions (PBS). Alexa measurements were 
obtained on free succinimidyl ester derivatives in PBS.   
* = values obtained from Chin et al., 2012. 
† 
=
 
values obtained from Mujumdar et al., 1993. 
 
 
